People_

Professor Anthony Keech

MBBS, VQE (USA), FRACP, MSc, FCSANZ, FAHMS

Professor of Medicine, Cardiology and Epidemiology, Faculty Medicine and Health
Director Cardiovascular Research, NHMRC Clinical Trials Centre (FMH)
NHMRC Senior Principal Research Fellow
Consultant Cardiologist, Royal Prince Alfred Hospital

Phone

+61 2 9562 5000 OR 500

Fax

+61 2 9562 5387

anthony.keech@sydney.edu.au

Details

Member of the Charles Perkins Centre

Websites

Related website

Biographical details

Professor Anthony (Tony) Keech is senior Principal Research Fellow and Director of Cardiovascular Research at the NHMRC Clinical Trials Centre (CTC), a flagship research organization at the University of Sydney.

Research interests

Professor Keech initiates, leads, designs and conducts clinical trials and meta-analyses in the fields of diabetes, CVD and beyond, and oversees a basic research program focused on identifying biomarkers for diagnosis and response to treatment of the vascular complications of diabetes. He also conducts Trial Methods Research, which involves developing further sophisticated methods of randomization and many other aspects of trial design and analysis.

He continues to lead the FIELD study of nearly 10,000 patients, comprising a number of substudies evaluating risk-related molecular and other biomarker data for vascular disease prediction and prevention. His team has identified major pathways of fenofibrate protection against retinopathy and amputations and is investigating the mechanisms of its renoprotective effects. Additionally, DNA methylation studies and microRNA studies are underway, complementing major biomarker work related to lipids, inflammation, oxidative stress and angiogenesis.

Other trials include START-UP, a RCT evaluating whether postoperative atrial pacing and prophylactic amiodarone drug therapy can safely and effectively eliminate post-surgical atrial fibrillation in patients undergoing arterial bypass or valve replacement surgery. He is co-chair of the LEAP study of lactoferrin in anaemia of pregnancy and is involved in the evaluation of an SSRI (sertraline) for reducing impulsivity in repeat violent offenders. He has published over 180 peer-reviewed papers, won more then $200 million in grant income, and authored a major text explaining how and why randomised trials are performed.

Associations

Committee Memberships

Australian Clinical Trials Alliance board member
NHMRC CTC Scientific Advisory Committee, Management Review Committee
Chair, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
Management Committee, Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Co-principal investigator, Cholesterol Treatment Trialists Collaboration (CTTC)
Virtual Coordinating Centre for International Collaborative Cardiovascular Research

Themes

Obesity, Diabetes and Cardiovascular Disease

Keywords

Cardiovascular diseases, Diabetes, Diabetic retinopathy, Epidemiology, Lipid metabolism

Clinical speciality

Cardiology

Selected publications

Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials

(AMPCo, 2007)

Expand all

Edited Books

Keech, A., Gebski, V., Pike, R. (2007). Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials. Sydney: AMPCo.

Book Chapters

Donaghue, K., Keech, A., Craig, M., O'Connell, P. (2012). A 'cure' for diabetes and its complications. In Louise A. Baur, Stephen M. Twigg, Roger S.Magnusson (Eds.), A Modern Epidemic: Expert Perspectives on Obesity and Diabetes, (pp. 401-420). Sydney, Australia: Sydney University Press.
Cook, D., Keech, A., Gebski, V., Pike, R., Wonders, S. (2008). Balancing the outcomes: reporting harms (adverse events). In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 132-142). Sydney: AMPCo.
Keech, A., Gebski, V., Forder, P. (2007). Allocation concealment and blinding: when ignorance is bliss. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 54-64). Sydney: AMPCo.
Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.
Keech, A., Gebski, V., Vachan, B. (2007). Flow of participants in randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 347-349). Sydney: AMPCo.
Keech, A., Gebski, V., Heritier, S. (2007). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 92-98). Sydney: AMPCo.
Keech, A., Ghersi, D., Gebski, V., Pike, R. (2007). Introducing the report of a randomised controlled trial: the title, abstract, scientific background and rationale. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 8-10). Sydney: AMPCo.
O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.
Keech, A., Gebski, V. (2007). Managing the resource demand of a large sample in clinical trials: can you succeed with fewer subjects? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 39-45). Sydney: AMPCo.
Keech, A., Gebski, V., Lord, S. (2007). Multiple analyses in clinical trials: sound science or data dredging? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 123-131). Sydney: AMPCo.
Gebski, V., Beller, E., Keech, A., Van Der Weyden, M. (2007). Randomised Controlled Trials: Elements of a Good Study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 7-22). Sydney: AMPCo.
Keech, A., Gebski, V., Beller, E., Van Der Weyden, M. (2007). Randomised controlled trials: elements of a good study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 1-7). Sydney: AMPCo.
Brighton, J., Gebski, V., Keech, A. (2007). Specifying intervention in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 16-20). Sydney: AMPCo.

show 10 more

Journals

Burns, B., Marschner, I., Eggins, R., Buscher, H., Morton, R., Bendall, J., Keech, A., Dennis, M. (2024). A randomized trial of expedited intra-arrest transfer versus more extended on-scene resuscitation for refractory out of hospital cardiac arrest: Rationale and design of the EVIDENCE trial. American Heart Journal, 267, 22-32. [More Information]
Tucker, W., Tucker, B., Januszewski, A., Jenkins, A., Keech, A., Kestenbaum, B., Allison, M., Rye, K., Ong, K. (2024). Association of circulating fibroblast growth factor 21 levels with all-cause and cardiovascular mortality: The multi-ethnic study of atherosclerosis. Clinica Chimica Acta, 555, 117799. [More Information]
Tucker, B., Goonetilleke, N., Patel, S., Keech, A. (2024). Colchicine in atherosclerotic cardiovascular disease. Heart, 110(9), 618-625. [More Information]
Januszewski, A., Young, H., Ong, K., Li, L., O'Connell, R., Lyons, T., Kelly, C., Zaharieva, D., Sullivan, D., Scott, R., Keech, A., Jenkins, A. (2024). Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate. Journal of Diabetes Investigation. [More Information]
Rehan, R., Ng, M., Virk, S., Wong, C., Passam, F., Layland, J., Keech, A., Yong, A., White, H., Fearon, W. (2024). Intracoronary thrombolysis in ST-elevation myocardial infarction: A systematic review and meta-analysis. Heart, , heartjnl-2024-324078. [More Information]
Mihaylova, B., Wu, R., Zhou, J., Williams, C., Schlackow, I., Emberson, J., Reith, C., Keech, A., Robson, J., Simes, R. (2024). Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study. The Lancet Regional Health. Europe, 40, 100887. [More Information]
Mihaylova, B., Armitage, J., Gray, A., Simes, J., Baigent, C., Wu, R., Zhou, J., Williams, C., Schlackow, I., Emberson, J., Keech, A., et al (2024). Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study. Heart. [More Information]
Wu, R., Gray, A., Simes, R., Baigent, C., Mihaylova, B., Williams, C., Zhou, J., Schlackow, I., Emberson, J., Reith, C., Keech, A., et al (2024). Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model. British Journal of General Practice, 74(740), e189-e198. [More Information]
McClintick, D., Monsalvo, M., Atar, D., Keech, A., Giugliano, R., Sabatine, M., O'Donoghue, M., De Ferrari, G., Ferreira, J., Ran, X., et al (2024). Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. Journal of the American College of Cardiology, 83(6), 652-664. [More Information]
Jenkins, A., O'Connell, R., Januszewski, A., Webster, A., Davis, T., Jardine, M., Scott, R., Taskinen, M., Keech, A. (2024). Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes. Diabetes Research and Clinical Practice, 210, 111612-111612. [More Information]
Sheu, A., O'Connell, R., Jenkins, A., Tran, T., Drury, P., Sullivan, D., Li, L., Colman, P., O’Brien, R., Kesäniemi, Y., Keech, A., et al (2023). Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes - Metabolism: Research and Reviews. [More Information]
Smith, G., Abraham, M., de Bock, M., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., et al (2023). Impact of Missing Data on the Accuracy of Glucose Metrics from Continuous Glucose Monitoring Assessed Over a 2-Week Period. Diabetes Technology and Therapeutics, 25(5), 356-362. [More Information]
O'Rourke, M., Januszewski, A., Sullivan, D., Lengyel, I., Stewart, A., Arya, S., Ma, R., Galande, S., Hardikar, A., Joglekar, M., Keech, A., Jenkins, A., Molloy, M. (2023). Optimised plasma sample preparation and LC-MS analysis to support large-scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial. Proteomics - Clinical Applications. [More Information]
Zhou, J., Wu, R., Williams, C., Emberson, J., Reith, C., Keech, A., Robson, J., Armitage, J., Gray, A., Simes, R., et al (2023). Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK. PharmacoEconomics, 41(5), 547-559. [More Information]
Brazionis, L., Quinn, N., Dabbah, S., Ryan, C., Møller, D., Richardson, H., Keech, A., Januszewski, A., Grauslund, J., Rasmussen, M., Jenkins, A., et al (2023). Review and comparison of retinal vessel calibre and geometry software and their application to diabetes, cardiovascular disease, and dementia. Graefe's Archive for Clinical and Experimental Ophthalmology. [More Information]
Stewart, R., Kirby, A., White, H., Marschner, S., West, M., Thompson, P., Sullivan, D., Janus, E., Hunt, D., Kritharides, L., Keech, A., Simes, R., et al (2022). B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease. Journal of the American Heart Association, 11(13). [More Information]
Fagundes, A., Morrow, D., Oyama, K., Furtado, R., Zelniker, T., Tang, M., Kuder, J., Murphy, S., Hamer, A., Keech, A., et al (2022). Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. Journal of the American College of Cardiology, 80(9), 887-897. [More Information]
Trawley, S., Stephens, A., McAuley, S., Speight, J., Hendrieckx, C., Vogrin, S., Lee, M., Paldus, B., Bach, L., Burt, M., Holmes-Walker, J., Keech, A., et al (2022). Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 24(5), 350-356. [More Information]
Furtado, R., Fagundes, A., Oyama, K., Zelniker, T., Tang, M., Kuder, J., Murphy, S., Hamer, A., Wang, H., Keech, A., et al (2022). Effect of Evolocumab in Patients with Prior Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 15(3), 227-236. [More Information]
Robledo, K., Tarnow-Mordi, W., Rieger, I., Suresh, P., Martin, A., Yeung, C., Ghadge, A., Liley, H., Osborn, D., Morris, J., Hague, W., Kluckow, M., Keech, A., Kirby, A., Simes, R., et al (2022). Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trial. The Lancet Child and Adolescent Health, 6(3), 150-157. [More Information]
Tran, D., Gibson, H., Maiorana, A., Verrall, C., Baker, D., Clode, M., Lubans, D., Zannino, D., Bullock, A., Ferrie, S., Gosbell, S., Davis, G., Keech, A., Puranik, R., Majumdar, A., Ayer, J., Celermajer, D., Cordina, R., et al (2022). Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)—Rationale and Design. Frontiers in Pediatrics, 9, 799125. [More Information]
Quinn, N., Januszewski, A., Brazionis, L., O'Connell, R., Aryal, N., O'Day, J., Scott, R., Mitchell, P., Jenkins, A., Keech, A. (2022). Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy. Internal Medicine Journal, 52(4), 676-679. [More Information]
Drak, D., Fulcher, J., Kilian, J., Chong, J., Grover, R., Sindone, A., Adams, M., Lattimore, J., Keech, A. (2022). Guideline-based audit of the hospital management of heart failure with reduced ejection fraction. Internal Medicine Journal. [More Information]
Roberts, A., Fried, L., Dart, J., De Bock, M., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., et al (2022). Hybrid closed-loop therapy with a first-generation system increases confidence and independence in diabetes management in youth with type 1 diabetes. Diabetic Medicine, 39(9). [More Information]
O'Donoghue, M., Giugliano, R., Wiviott, S., Atar, D., Keech, A., Kuder, J., Im, K., Murphy, S., Flores-Arredondo, J., López, J., et al (2022). Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 146(15), 1109-1119. [More Information]
Korthauer, L., Giugliano, R., Guo, J., Sabatine, M., Sever, P., Keech, A., Atar, D., Kurtz, C., Ruff, C., Mach, F., et al (2022). No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PloS One, 17(2023-04-04 00:00:00). [More Information]
Atkinson-Briggs, S., Ryan, C., Keech, A., Jenkins, A., Brazionis, L. (2022). Nurse-led vascular risk assessment in a regional Victorian Indigenous primary care diabetes clinic: An integrated Diabetes Education and Eye disease Screening [iDEES] study. Journal of Advanced Nursing, 78(11), 3652-3661. [More Information]
Cheng, F., Luk, A., Wu, H., Tam, C., Lim, C., Fan, B., Jiang, G., Carroll, L., Yang, A., Lau, E., Keech, A., Joglekar, M., Hardikar, A., Jenkins, A., Ma, R., et al (2022). Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register. Diabetologia, 65(2), 375-386. [More Information]
Rao, B., Quinn, N., Januszewski, A., Peto, T., Brazionis, L., Aryal, N., O'Connell, R., Li, L., Summanen, P., Scott, R., Keech, A., Jenkins, A., et al (2022). Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Research and Clinical Practice, 186, 109835-1-109835-6. [More Information]
Cheng, F., Luk, A., Shi, M., Huang, C., Jiang, G., Yang, A., Wu, H., Lim, C., Tam, C., Fan, B., Carroll, L., Keech, A., Joglekar, M., Hardikar, A., Jenkins, A., et al (2022). Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. Diabetes Care, 45(3), 701-709. [More Information]
Abraham, M., Smith, G., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., de Bock, M., et al (2022). Snapshot of CGM Metrics in Adolescents and Adults Achieving Target HbA1c Versus Those Not Meeting Target HbA1c. Diabetes Technology and Therapeutics, 24(9), 677-679. [More Information]
Atkinson-Briggs, S., Jenkins, A., Keech, A., Ryan, C., Brazionis, L. (2021). A model of culturally-informed integrated diabetes education and eye screening in indigenous primary care services and specialist diabetes clinics: Study protocol. Journal of Advanced Nursing, 77(3), 1578-1590. [More Information]
Brazionis, L., Keech, A., Ryan, C., Brown, A., O'Neal, D., Boffa, J., Bursell, S., Jenkins, A. (2021). Associations with sight-threatening diabetic macular oedema among Indigenous adults with type 2 diabetes attending an Indigenous primary care clinic in remote Australia: A Centre of Research Excellence in Diabetic Retinopathy and Telehealth Eye and Associated Medical Services Network study. BMJ Open Ophthalmology, 6(1), e000559. [More Information]
Marston, N., Giugliano, R., Park, J., Ruzza, A., Sever, P., Keech, A., Sabatine, M. (2021). Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl. Circulation, 144(21), 1732-1734. [More Information]
Marston, N., Patel, P., Kamanu, F., Nordio, F., Melloni, G., Roselli, C., Gurmu, Y., Weng, L., Bonaca, M., Giugliano, R., Keech, A., et al (2021). Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. Circulation, 143(5), 470-478. [More Information]
Marston, N., Oyama, K., Jarolim, P., Tang, M., Sever, P., Keech, A., Pineda, A., Wang, H., Giugliano, R., Sabatine, M., et al (2021). Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation, 144(3), 249-251. [More Information]
Abraham, M., De Bock, M., Smith, G., Dart, J., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., et al (2021). Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents with Type 1 Diabetes: A Randomized Clinical Trial. JAMA Pediatrics, 175(12), 1227-1235. [More Information]
Oyama, K., Giugliano, R., Tang, M., Bonaca, M., Saver, J., Murphy, S., Ruzza, A., Keech, A., Sever, P., Sabatine, M., et al (2021). Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. European Heart Journal, 42(47), 4821-4829. [More Information]
Oyama, K., Furtado, R., Fagundes, A., Zelniker, T., Tang, M., Kuder, J., Murphy, S., Hamer, A., Wang, H., Keech, A., et al (2021). Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. Journal of the American College of Cardiology, 77(3), 259-267. [More Information]
Keech, A., Oyama, K., Sever, P., Tang, M., Murphy, S., Hirayama, A., Lu, C., Tay, L., Deedwania, P., Siu, C., et al (2021). Efficacy and safety of long-term evolocumab use among Asian subjects - A subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (fourier) trial - A s. Circulation Journal, 85(11), 2063-2070. [More Information]
Fiolet, A., Opstal, T., Mosterd, A., Eikelboom, J., Jolly, S., Keech, A., Kelly, P., Tong, D., Layland, J., Thompson, P., et al (2021). Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal, 42(28), 2765-2775. [More Information]
Deedwania, P., Murphy, S., Scheen, A., Badariene, J., Pineda, A., Honarpour, N., Keech, A., Sever, P., Pedersen, T., Sabatine, M., et al (2021). Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: Secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiology, 6(2), 139-147. [More Information]
Marston, N., Melloni, G., Gurmu, Y., Bonaca, M., Kamanu, F., Roselli, C., Lee, C., Cavallari, I., Giugliano, R., Scirica, B., Keech, A., et al (2021). Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation. Genomic and Precision Medicine, 14(1), e003006. [More Information]
Januszewski, A., Cho, Y., Joglekar, M., Farr, R., Scott, E., Wong, W., Carroll, L., Loh, Y., Benitez-Aguirre, P., Keech, A., Craig, M., Hardikar, A., Donaghue, K., Jenkins, A., et al (2021). Insulin micro-secretion in Type 1 diabetes and related microRNA profiles. Scientific Reports, 11(1), 11727. [More Information]
Sever, P., Gouni-Berthold, I., Keech, A., Giugliano, R., Pedersen, T., Im, K., Wang, H., Knusel, B., Sabatine, M., O’Donoghue, M. (2021). LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. European Journal of Preventive Cardiology, 28, 805-812. [More Information]
McAuley, S., Vogrin, S., Lee, M., Paldus, B., Trawley, S., De Bock, M., Abraham, M., Bach, L., Burt, M., Cohen, N., Jenkins, A., Keech, A., et al (2021). Less Nocturnal Hypoglycemia but Equivalent Time in Range among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 23(6), 460-466. [More Information]
Lu, J., Vogrin, S., McAuley, S., Lee, M., Paldus, B., Bach, L., Burt, M., Clarke, P., Cohen, N., Colman, P., Holmes-Walker, J., Jenkins, A., Keech, A., O'Neal, D., et al (2021). Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 179, 109000. [More Information]
Atar, D., Jukema, J., Molemans, B., Taub, P., Goto, S., Mach, F., CerezoOlmos, C., Underberg, J., Keech, A., Tokgozoglu, L., et al (2021). New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis, 319, 51-61. [More Information]
Snir, A., Wilson, M., Ju, L., Zhao, Y., Wong, S., Khor, L., Naoum, C., Wong, K., Keech, A., Celermajer, D., Ng, M. (2021). Novel Pressure-Regulated Deployment Strategy for Improving the Safety and Efficacy of Balloon-Expandable Transcatheter Aortic Valves. J A C C: Cardiovascular Interventions, 14(22), 2503-2515. [More Information]
Atkinson-Briggs, S., Jenkins, A., Keech, A., Ryan, C., Brazionis, L. (2021). Prevalence of diabetic retinopathy and reduced vision among indigenous Australians in the nurse-led integrated Diabetes Education and Eye Screening study in a regional primary care clinic. Internal Medicine Journal. [More Information]
Bubb, K., Harmer, J., Finemore, M., Aitken, S., Ali, Z., Billot, L., Chow, C., Golledge, J., Mister, R., Gray, M., Grieve, S., Keech, A., Patel, S., Figtree, G., et al (2021). Protocol for the Stimulating β3- Adrenergic Receptors for Peripheral Artery Disease (STAR- PAD) trial: a double- blinded, randomised, placebo- controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease. BMJ Open, 11(9), e049858-1-e049858-10. [More Information]
Januszewski, A., Chen, D., Scott, R., O'Connell, R., Aryal, N., Sullivan, D., Watts, G., Taskinen, M., Barter, P., Best, J., Simes, R., Keech, A., Jenkins, A. (2021). Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 11(1), 18708. [More Information]
Quinn, N., Yang, F., Ryan, C., Bursell, S., Keech, A., Atkinson-Briggs, S., Jenkins, A., Brazionis, L. (2021). Screening for Diabetic Retinopathy and Reduced Vision among Indigenous Australians in Top End Primary Care Health Services: a TEAMSnet Sub-study. Internal Medicine Journal, 51(11), 1897-1905. [More Information]
Butler, T., Schofield, P., Knight, L., Ton, B., Greenberg, D., Scott, R., Grant, L., Keech, A., Gebski, V., Jones, J., et al (2021). Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): Protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. BMJ Open, 11(9), e044656. [More Information]
Cheng, F., Luk, A., Wu, H., Lim, C., Carroll, L., Tam, C., Fan, B., Yang, A., Lau, E., Ng, A., Keech, A., Joglekar, M., Jenkins, A., Hardikar, A., Ma, R., et al (2021). Shortened relative leukocyte telomere length is associated with all-cause mortality in type 2 diabetes- analysis from the Hong Kong Diabetes Register. Diabetes Research and Clinical Practice, 173, 108649. [More Information]
Woldendorp, K., Doyle, M., Black, D., Ng, M., Keech, A., Grieve, S., Bannon, P. (2021). Subclinical valve thrombosis in transcatheter aortic valve implantation: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 162(5), 1491-1499.e2. [More Information]
Wittert, G., Bracken, K., Robledo, K., Grossmann, M., Yeap, B., Handelsman, D., Stuckey, B., Conway, A., Inder, W., McLachlan, R., Hague, W., Jenkins, A., Gebski, V., Keech, A., et al (2021). Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. The Lancet Diabetes and Endocrinology, 9(1), 32-45. [More Information]
Cao, J., Lee, S., Dunkley, S., Adams, M., Keech, A. (2021). The case for extended thromboprophylaxis in medically hospitalised patients - not yet made. European Journal of Preventive Cardiology, 28(11), 1167-1174. [More Information]
Ong, K., Wu, L., Januszewski, A., O'Connell, R., Xu, A., Scott, R., Sullivan, D., Rye, K., Li, H., Ma, R., Li, L., Gebski, V., Jenkins, A., Keech, A., et al (2021). The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diabetes and Vascular Disease Research, 18(4). [More Information]
Shah, K., Elder, D., Nguyen, M., Turner, L., Doyle, M., Woldendorp, K., Seco, M., Law, C., Wilson, M., Keech, A., Ng, M., Morton, R. (2021). Transcatheter Aortic Valve Implantation (TAVI) Versus Surgical Aortic Valve Replacement for Aortic Stenosis (SAVR): A Cost-Comparison Study. Heart, Lung, and Circulation, 30(12), 1918-1928. [More Information]
Waldman, B., Cartwright, B., Keech, A., Byrom, M., D'Silva, D., Weaver, J. (2021). Transesophageal Echocardiographic Diagnosis of Cardiac Rupture During Extracorporeal Membrane Oxygenation–Assisted Percutaneous Coronary Intervention. Journal of Cardiothoracic and Vascular Anesthesia, 35(3), 910-913. [More Information]
Barraclough, J., Joglekar, M., Januszewski, A., Martínez, G., Celermajer, D., Keech, A., Hardikar, A., Patel, S. (2020). A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. Journal of Cardiovascular Pharmacology and Therapeutics, 25(5), 444-455. [More Information]
Sivashanmugarajah, A., Fulcher, J., Sullivan, D., Elam, M., Jenkins, A., Keech, A. (2020). Author reply. Internal Medicine Journal, 50(4), 507-508. [More Information]
Gencer, B., Mach, F., Guo, J., Im, K., Ruzza, A., Wang, H., Kurtz, C., Pedersen, T., Keech, A., Ott, B., et al (2020). Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 75(18), 2283-2293. [More Information]
Wiviott, S., Giugliano, R., Morrow, D., De Ferrari, G., Lewis, B., Huber, K., Kuder, J., Murphy, S., Forni, D., Kurtz, C., Keech, A., et al (2020). Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. JAMA Cardiology, 5(7), 787-793. [More Information]
Gencer, B., Marston, N., Im, K., Cannon, C., Sever, P., Keech, A., Braunwald, E., Giugliano, R., Sabatine, M. (2020). Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. The Lancet, 396(10263), 1637-1643. [More Information]
Gencer, B., Mach, F., Murphy, S., De Ferrari, G., Huber, K., Lewis, B., Ferreira, J., Kurtz, C., Wang, H., Honarpour, N., Keech, A., et al (2020). Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial Infarction: A Prespecified Secondary Analysis from the FOURIER Trial. JAMA Cardiology, 5(8), 952-957. [More Information]
Januszewski, A., Watson, C., O’Neill, V., McDonald, K., Ledwidge, M., Robson, T., Jenkins, A., Keech, A., McClements, L. (2020). FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Scientific Reports, 10(1), 1-8. [More Information]
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G., Wilcox, I., Keech, A., Rodgers, A., Lal, S. (2020). Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327037 participants. The Lancet Diabetes & Endocrinology, 8(1), 36-49. [More Information]
Scott, E., Januszewski, A., O'Connell, R., Fulcher, G., Scott, R., Kesaniemi, A., Wu, L., Colagiuri, S., Keech, A., Jenkins, A. (2020). Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. Journal of Clinical Endocrinology and Metabolism, 105(10), 1-12. [More Information]
Marston, N., Kamanu, F., Nordio, F., Gurmu, Y., Roselli, C., Sever, P., Pedersen, T., Keech, A., Wang, H., Lira Pineda, A., et al (2020). Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation, 141(8), 616-623. [More Information]
Fulcher, J., Keech, A., Simes, R., Baigent, C., Collins, R. (2020). Questioning statin therapy for older patients – Authors' reply. The Lancet, 395(10240), 1832-1833. [More Information]
Khandkar, C., Vaidya, K., Penglase, R., Cai, K., Shin, J., Hunyor, I., Keech, A., McGill, N. (2020). Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema. Internal Medicine Journal, 50(1), 127-128. [More Information]
Ong, K., Wu, L., Januszewski, A., O'Connell, R., Xu, A., Rye, K., Ma, R., Li, H., Jenkins, A., Jia, W., Keech, A. (2020). Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Research and Clinical Practice, 169, 108450. [More Information]
Cheng, F., Luk, A., Tam, C., Fan, B., Wu, H., Yang, A., Lau, E., Ng, A., Lim, C., Lee, H., Keech, A., Joglekar, M., Jenkins, A., Hardikar, A., Ma, R., et al (2020). Shortened relative leukocyte telomere length is associated with prevalent and incident cardiovascular complications in type 2 diabetes: Analysis from the Hong Kong diabetes register. Diabetes Care, 43(9), 2257-2265. [More Information]
McAuley, S., Lee, M., Paldus, B., Vogrin, S., de Bock, M., Abraham, M., Bach, L., Burt, M., Cohen, N., Colman, P., Holmes-Walker, J., Keech, A., et al (2020). Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: A randomizedcontrolled trial. Diabetes Care, 43(12), 3024-3033. [More Information]
Giugliano, R., Pedersen, T., Saver, J., Sever, P., Keech, A., Bohula, E., Murphy, S., Wasserman, S., Honarpour, N., Wang, H., et al (2020). Stroke Prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients with Stable Atherosclerosis. Stroke, 51(5), 1546-1554. [More Information]
Tarnow-Mordi, W., Abdel-Latif, M., Martin, A., Pammi, M., Robledo, K., Manzoni, P., Osborn, D., Lui, K., Keech, A., Hague, W., Ghadge, A., Brown, R., Isaacs, D., Gordon, A., Askie, L., Deshpande, G., Tracy, M., Sinn, J., Simes, R., et al (2020). The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial. The Lancet Child and Adolescent Health, 4(6), 444-454. [More Information]
Marston, N., Gurmu, Y., Melloni, G., Bonaca, M., Gencer, B., Sever, P., Pedersen, T., Keech, A., Roselli, C., Lubitz, S., et al (2020). The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 141(20), 1600-1607. [More Information]
Cao, J., Waldman, B., O'Connell, R., Sullivan, D., Scott, R., Aryal, N., Gebski, V., Marschner, I., Taskinen, M., Simes, R., McGill, N., Jenkins, A., Keech, A. (2020). Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes, Obesity and Metabolism, 22(8), 1388-1396. [More Information]
Bracken, K., Keech, A., Hague, W., Allan, C., Conway, A., Daniel, M., Gebski, V., Grossmann, M., Handelsman, D., Inder, W., Jenkins, A., Robledo, K., et al (2019). A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial. Clinical Trials, 16(6), 589-598. [More Information]
Mann Zhuang Mills, J., Januszewski, A., Robinson, B., Traill, C., Jenkins, A., Keech, A. (2019). Attractions and barriers to Australian physician-researcher careers. Internal Medicine Journal, 49(2), 171-181. [More Information]
Murphy, S., Pedersen, T., Gaciong, Z., Ceska, R., Ezhov, M., Connolly, D., Jukema, J., Toth, K., Tikkanen, M., Im, K., Keech, A., et al (2019). Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients with Cardiovascular Disease: A Prespecified Analysis from the FOURIER Trial. JAMA Cardiology, 4(7), 613-619. [More Information]
Charytan, D., Sabatine, M., Pedersen, T., Im, K., Park, J., Pineda, A., Wasserman, S., Deedwania, P., Olsson, A., Sever, P., Keech, A., et al (2019). Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. Journal of the American College of Cardiology, 73(23), 2961-2970. [More Information]
Yuan, J., Tan, J., Rajamani, K., Solly, E., King, E., Lecce, L., Simpson, P., Lam, M., Jenkins, A., Bursill, C., Keech, A., Ng, M. (2019). Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARa-Independent Modulation of Thioredoxin Interacting Protein. Diabetes, 68(5), 1040-1053. [More Information]
Xu, D., Jenkins, A., Ryan, C., Keech, A., Brown, A., Bursell, S., O'Dea, K., Brazionis, L. (2019). Health-related behaviours in a remote Indigenous population with Type 2 diabetes: a Central Australian primary care survey in the Telehealth Eye and Associated Medical Services Network [TEAMSnet] project. Diabetic Medicine, 36(12), 1659-1670. [More Information]
Ong, K., Hui, N., Januszewski, A., Kaakoush, N., Xu, A., Fayyad, R., DeMicco, D., Jenkins, A., Keech, A., Waters, D., et al (2019). High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the treating to new targets [TNT] study). Metabolism: Clinical and Experimental, 93, 93-99. [More Information]
Atkinson-Briggs, S., Jenkins, A., Ryan, C., Keech, A., Brazionis, L. (2019). Integrating diabetic retinopathy screening within diabetes education services in Australia's diabetes and indigenous primary care clinics. Internal Medicine Journal, 49(6), 797-800. [More Information]
Qamar, A., Giugliano, R., Keech, A., Kuder, J., Murphy, S., Kurtz, C., Wasserman, S., Sever, P., Pedersen, T., Sabatine, M. (2019). Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA Cardiology, 4(1), 59-63. [More Information]
O'Donoghue, M., Fazio, S., Giugliano, R., Stroes, E., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S., Ceska, R., Keech, A., et al (2019). Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial. Circulation, 139(12), 1483-1492. [More Information]
Scirica, B., Bohula, E., Dwyer, J., Qamar, A., Inzucchi, S., Mcguire, D., Keech, A., Smith, S., Murphy, S., Im, K., et al (2019). Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 139(3), 366-375. [More Information]
Bracken, K., Hague, W., Keech, A., Conway, A., Handelsman, D., Grossmann, M., Jesudason, D., Stuckey, B., Yeap, B., Inder, W., Robledo, K., et al (2019). Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategies. Trials, 20(1), 1-14. [More Information]
Bracken, K., Askie, L., Keech, A., Hague, W., Wittert, G. (2019). Recruitment strategies in randomised controlled trials of men aged 50 years and older: a systematic review. BMJ Open, 9(4), 1-17. [More Information]
Sutanto, S., McLennan, S., Keech, A., Twigg, S. (2019). Shortening of telomere length by metabolic factors in diabetes: protective effects of fenofibrate. Journal of Cell Communication and Signaling, 13(4), 523-530. [More Information]
Sivashanmugarajah, A., Fulcher, J., Sullivan, D., Elam, M., Jenkins, A., Keech, A. (2019). Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects. Internal Medicine Journal, 49(9), 1081-1091. [More Information]
Bracken, K., Keech, A., Hague, W., Kirby, A., Robledo, K., Allan, C., Conway, A., Daniel, M., Gebski, V., Grossmann, M., Handelsman, D., Jenkins, A., et al (2019). Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial. Journal of Clinical Epidemiology, 112, 45-52. [More Information]
Wittert, G., Atlantis, E., Allan, C., Bracken, K., Conway, A., Daniel, M., Gebski, V., Grossmann, M., Hague, W., Handelsman, D., Jenkins, A., Keech, A., Robledo, K., et al (2019). Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomised controlled trial. Diabetes, Obesity and Metabolism, 21(4), 772-780. [More Information]
Bohula, E., Wiviott, S., Mcguire, D., Inzucchi, S., Kuder, J., Im, K., Fanola, C., Qamar, A., Brown, C., Budaj, A., Keech, A., et al (2018). Cardiovascular safety of lorcaserin in overweight or obese patients. New England Journal of Medicine, 379(12), 1107-1117. [More Information]
Sabatine, M., De Ferrari, G., Giugliano, R., Huber, K., Lewis, B., Ferreira, J., Kuder, J., Murphy, S., Wiviott, S., Kurtz, C., Keech, A., et al (2018). Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. Circulation, 38(6), 756-766. [More Information]
Giugliano, R., Keech, A., Sever, P., Pedersen, T., Sabatine, M. (2018). Clinical benefits of evolocumab appear less than hoped – Authors' reply. The Lancet, 391(10124), 934-935. [More Information]
Martin, S., Giugliano, R., Murphy, S., Wasserman, S., Stein, E., Ceska, R., Lopez-Miranda, J., Georgiev, B., Lorenzatti, A., Tikkanen, M., Keech, A., et al (2018). Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, friedewald estimation, and preparative ultracentrifugation insights from the FOURIER trial. JAMA Cardiology, 3(8), 749-753. [More Information]
Simes, R., Robledo, K., White, H., Espinoza, D., Stewart, R., Sullivan, D., Zeller, T., Hague, W., Nestel, P., Glasziou, P., Keech, A., et al (2018). D-dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events and Cancer in Patients with Stable Coronary Heart Disease: LIPID Study. Circulation, 138(7), 712-723. [More Information]
Tarnow-Mordi, W., Morris, J., Kirby, A., Robledo, K., Askie, L., Brown, R., Evans, N., Finlayson, S., Fogarty, M., Gebski, V., Ghadge, A., Hague, W., Isaacs, D., Jeffery, M., Keech, A., Kluckow, M., Popat, H., Sebastian, L., Liley, H., Osborn, D., Simes, R., et al (2018). Delayed Versus Immediate Cord Clamping in Preterm Infants. Obstetrical and Gynecological Survey, 73(5), 265-266. [More Information]
Bohula, E., Scirica, B., Fanola, C., Inzucchi, S., Keech, A., Mcguire, D., Smith, S., Abrahamsen, T., Francis, B., Miao, W., et al (2018). Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American Heart Journal, 202, 39-48. [More Information]
Brazionisb, L., Jenkins, A., Keech, A., Ryan, C., Brown, A., Boffa, J., Bursell, S. (2018). Diabetic retinopathy in a remote Indigenous primary healthcare population: a Central Australian diabetic retinopathy screening study in the Telehealth Eye and Associated Medical Services Network project. Diabetic Medicine, 35(5), 630-639. [More Information]
McAuley, S., De Bock, M., Sundararajan, V., Lee, M., Paldus, B., Ambler, G., Bach, L., Burt, M., Cameron, F., Clarke, P., Holmes-Walker, J., Jenkins, A., Keech, A., et al (2018). Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 8(6), 1-10. [More Information]
Waldman, B., Ansquer, J., Sullivan, D., Jenkins, A., McGill, N., Buizen, L., Davis, T., Best, J., Li, L., Feher, M., Gebski, V., Keech, A., et al (2018). Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. The Lancet Diabetes & Endocrinology, 6(4), 310-318. [More Information]
Bohula, E., Scirica, B., Inzucchi, S., Mcguire, D., Keech, A., Smith, S., Kanevsky, E., Murphy, S., Leiter, L., Dwyer, J., et al (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. The Lancet, 392(10161), 2269-2279. [More Information]
Harmer, J., Keech, A., Veillard, A., Skilton, M., Watts, G., Celermajer, D. (2018). Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: a FIELD substudy. Diabetes Research and Clinical Practice, 141, 156-167. [More Information]
Bohula, E., Giugliano, R., Leiter, L., Verma, S., Park, J., Sever, P., Pineda, A., Honarpour, N., Wang, H., Murphy, S., Keech, A., et al (2018). Inflammatory and cholesterol risk in the FOURIER trial. Circulation, 138(2), 131-140. [More Information]
Bonaca, M., Nault, P., Giugliano, R., Keech, A., Pineda, A., Kanevsky, E., Kuder, J., Murphy, S., Jukema, J., Lewis, B., et al (2018). Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation, 137(4), 338-350. [More Information]
Sullivan, D., Bonnitcha, P., Spinks, C., Keech, A. (2018). PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More. Circulation. Genomic and Precision Medicine, 11(7), 1-3. [More Information]
Koopal, C., Visseren, F., Westerink, J., van der Graaf, Y., Ginsberg, H., Keech, A. (2018). Predicting the effect of fenofibrate on cardiovascular risk for individual patients with type 2 diabetes. Diabetes Care, 41(6), 1244-1250. [More Information]
Larsson, C., Januszewski, A., McGrath, R., Ludvigsson, J., Keech, A., MacIsaac, R., Ward, G., O'Neal, D., Fulcher, G., Jenkins, A. (2018). Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with Type 1 diabetes is common. Internal Medicine Journal, 48(9), 1080-1086. [More Information]
Brazionis, L., Jenkins, A., Keech, A., Ryan, C., Bursell, S. (2017). An evaluation of the telehealth facilitation of diabetes and cardiovascular care in remote Australian Indigenous communities: - Protocol for the telehealth eye and associated medical services network [TEAMSnet] project, a pre-post study design. BMC Health Services Research, 17(1), 1-12. [More Information]
Ong, K., O'Connell, R., Januszewski, A., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Waldman, B., Simes, R., Rye, K., Keech, A., et al (2017). Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study. Clinical Chemistry, 63(7), 1261-1270. [More Information]
Sabatine, M., Leiter, L., Wiviott, S., Giugliano, R., Deedwania, P., De Ferrari, G., Murphy, S., Kuder, J., Gouni-Berthold, I., Keech, A., et al (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The Lancet Diabetes & Endocrinology, 5(12), 941-950. [More Information]
Giugliano, R., Pedersen, T., Park, J., De Ferrari, G., Gaciong, Z., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Keech, A., et al (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. The Lancet, 390(10106), 1962-1971. [More Information]
Giugliano, R., Keech, A., Murphy, S., Huber, K., Tokgozoglu, S., Lewis, B., Ferreira, J., Pineda, A., Somaratne, R., Sever, P., et al (2017). Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiology, 2(12), 1385-1391. [More Information]
Giugliano, R., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T., et al (2017). Cognitive function in a randomized trial of evolocumab. New England Journal of Medicine, 377(7), 633-643. [More Information]
Fonarow, G., Keech, A., Pedersen, T., Giugliano, R., Sever, P., Lindgren, P., van Hout, B., Villa, G., Qian, Y., Somaratne, R., et al (2017). Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiology, 2(10), 1069-1078. [More Information]
Tarnow-Mordi, W., Morris, J., Kirby, A., Robledo, K., Askie, L., Brown, R., Evans, N., Finlayson, S., Fogarty, M., Gebski, V., Ghadge, A., Hague, W., Isaacs, D., Jeffery, M., Keech, A., Kluckow, M., Popat, H., Sebastian, L., Liley, H., Osborn, D., Simes, R., et al (2017). Delayed versus Immediate Cord Clamping in Preterm Infants. New England Journal of Medicine, 377(25), 2445-2455. [More Information]
Giugliano, R., Mach, F., Zavitz, K., Kurtz, C., Schneider, J., Wang, H., Keech, A., Pedersen, T., Sabatine, M., Sever, P., et al (2017). Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clinical Cardiology, 40(2), 59-65. [More Information]
Sabatine, M., Giugliano, R., Keech, A., Honarpour, N., Wiviott, S., Murphy, S., Kuder, J., Wang, H., Liu, T., Wasserman, S., et al (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713-1722. [More Information]
Waldman, B., Jenkins, A., Sullivan, D., Ng, M., Keech, A. (2017). HDL as a Target for Glycemic Control. Current Drug Targets, 18(6), 651-673. [More Information]
Sharman, J., Stanton, T., Reid, C., Keech, A., Roberts-Thomson, P., Stewart, S., Greenough, R., Stowasser, M., Abhayaratna, W. (2017). Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). Contemporary Clinical Trials, 62, 37-42. [More Information]
Keech, A., Jenkins, A. (2017). Triglyceride-lowering trials. Current Opinion in Lipidology, 28(6), 477-487. [More Information]
Gray, B., Kirby, A., Kabunga, P., Freedman, S., Yeates, L., Kanthan, A., Medi, C., Keech, A., Semsarian, C., Sy, R. (2017). Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications. Heart Rhythm, 14(6), 866-874. [More Information]
Chia, N., Fulcher, J., Keech, A. (2016). Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): An evidence-based mnemonic for the treatment of systolic heart failure. Internal Medicine Journal, 46(6), 653-662. [More Information]
Oei, J., Ghadge, A., Coates, E., Wright, I., Saugstad, O., Vento, M., Buonocore, G., Nagashima, T., Suzuki, K., Hosono, S., Askie, L., Keech, A., Tarnow-Mordi, W., et al (2016). Clinicians in 25 countries prefer to use lower levels of oxygen to resuscitate preterm infants at birth. Acta Paediatrica, 105(9), 1061-1066. [More Information]
Bursell, S., Zang, S., Keech, A., Jenkins, A. (2016). Evolving telehealth reimbursement in Australia. Internal Medicine Journal, 46(8), 977-981. [More Information]
Abed, H., Fulcher, J., Kilborn, M., Keech, A. (2016). Inappropriate sinus tachycardia: focus on ivabradine. Internal Medicine Journal, 46(8), 875-883. [More Information]
Hague, W., Simes, R., Kirby, A., Keech, A., White, H., Hunt, D., Nestel, P., Colquhoun, D., Pater, H., Stewart, R., Sullivan, D., et al (2016). Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study. Circulation, 133(19), 1851-1860. [More Information]
Williams, K., Sullivan, D., Veillard, A., O'Brien, R., George, J., Jenkins, A., Young, S., Ehnholm, C., Duffield, A., Twigg, S., Keech, A. (2016). Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine, 33(3), 356-364. [More Information]
Sherrah, A., Andvik, S., van der Linde, D., Davies, L., Bannon, P., Padang, R., Vallely, M., Wilson, M., Keech, A., Jeremy, R. (2016). Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm. Journal of the American College of Cardiology, 67(6), 618-626. [More Information]
Williams, K., Sullivan, D., Nicholson, G., George, J., Jenkins, A., Januszewski, A., Gebski, V., Manning, P., Tan, Y., Donoghoe, M., Buizen, L., Twigg, S., Keech, A., et al (2016). Opposite associations between alanine aminotransferase and Î³-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 65(5), 783-793. [More Information]
Tarnow-Mordi, W., Stenson, B., Kirby, A., Juszczak, E., Donoghoe, M., Deshpande, S., Morley, C., King, A., Doyle, L., Fleck, B., Hague, W., Gebski, V., Ghadge, A., Keech, A., Kluckow, M., Evans, N., Simes, R., et al (2016). Outcomes of two trials of oxygen-saturation targets in preterm infants. New England Journal of Medicine, 374(8), 749-760. [More Information]
Stern, K., Cho, Y., Benitez-Aguirre, P., Jenkins, A., McGill, M., Mitchell, P., Keech, A., Donaghue, K. (2016). QT interval, corrected for heart rate, is associated with HbA1c concentration and autonomic function in diabetes. Diabetic Medicine, 33(10), 1415-1421. [More Information]
Sabatine, M., Giugliano, R., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S., Scott, R., Sever, P., Pedersen, T. (2016). Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal, 173, 94-101. [More Information]
Januszewski, A., Sutanto, S., McLennan, S., O'Neal, D., Keech, A., Twigg, S., Jenkins, A. (2016). Shorter telomeres in adults with Type 1 diabetes correlate with diabetes duration, but only weakly with vascular function and risk factors. Diabetes Research and Clinical Practice, 117, 4-11. [More Information]
Traill, C., Januszewski, A., Larkins, R., Keech, A., Jenkins, A. (2016). Time to research Australian female physician-researchers. Internal Medicine Journal, 46(4), 412-419. [More Information]
Traill, C., Januszewski, A., Larkins, R., Keech, A., Jenkins, A. (2016). Time to research Australian physician-researchers. Internal Medicine Journal, 46(5), 550-558. [More Information]
Jenkins, A., Joglekar, M., Hardikar, A., Keech, A., O'Neal, D., Januszewski, A. (2015). Biomarkers in Diabetic Retinopathy. The Review of Diabetic Studies, 12(1-2), 159-195. [More Information]
Tonkin, A., Blankenberg, S., Kirby, A., Zeller, T., Colquhoun, D., Funke-Kaiser, A., Hague, W., Hunt, D., Keech, A., Nestel, P., Sullivan, D., Simes, R., et al (2015). Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. International Journal of Cardiology, 201, 499-507. [More Information]
Sullivan, D., Watts, G., Nicholls, S., Barter, P., Grenfell, R., Chow, C., Tonkin, A., Keech, A. (2015). Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review. Heart, Lung, and Circulation, 24(5), 495-502. [More Information]
Fulcher, J., O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., Simes, J., Collins, R., Kirby, A., Colhoun, H., Keech, A., et al (2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet, 385(9976), 1397-1405. [More Information]
Harmer, J., Keech, A., Veillard, A., Skilton, M., Marwick, T., Watts, G., Meredith, I., Celermajer, D. (2015). Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. Atherosclerosis, 242(1), 295-302. [More Information]
Swerdlow, D., Preiss, D., Kuchenbaecker, K., Holmes, M., Engmann, J., Shah, T., Sofat, R., Stender, S., Johnson, P., Scott, R., Keech, A., et al (2015). HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet, 385, 351-361. [More Information]
Chin, J., Fulcher, J., Jenkins, A., Keech, A. (2015). Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. Heart, Lung, and Circulation, 24(5), 480-487. [More Information]
Hardikar, A., Satoor, S., Karandikar, M., Joglekar, M., Puranik, A., Wong, W., Kumar, S., Limaye, A., Bhat, D., Januszewski, A., Keech, A., Jenkins, A., et al (2015). Multigenerational Undernutrition Increases Susceptibility to Obesity and Diabetes that Is Not Reversed after Dietary Recuperation. Cell Metabolism, 22(2), 312-319. [More Information]
Ong, K., Januszewski, A., O'Connell, R., Buizen, L., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Rye, K., Keech, A. (2015). Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 59(8), 2035-2044. [More Information]
Herrmann, M., Sullivan, D., Veillard, A., McCorquodale, T., Straub, I., Scott, R., Laakso, M., Topliss, D., Jenkins, A., Blankenberg, S., Keech, A., et al (2015). Serum 25-Hydroxy Vitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes. Diabetes Care, 38(3), 521-528. [More Information]
Ong, K., Januszewski, A., O'Connell, R., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Hung, W., Scott, R., Taskinen, M., Keech, A., Rye, K. (2015). The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 58(3), 464-473. [More Information]
White, H., Tonkin, A., Simes, R., Stewart, R., Robledo, K., Thompson, P., Colquhoun, D., West, M., Nestel, P., Sullivan, D., Keech, A., et al (2014). Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina. Journal of the American College of Cardiology, 63(4), 345-354. [More Information]
Harmer, J., Keech, A., Veillard, A., Skilton, M., Marwick, T., Watts, G., Meredith, I., Celermajer, D. (2014). Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. Diabetes Research and Clinical Practice, 106(2), 328-336. [More Information]
d'Emden, M., Jenkins, A., Li, L., Zannino, D., Robledo, K., Best, J., Stuckey, B., Park, K., Saltevo, J., Keech, A. (2014). Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia, 57(11), 2296-2303. [More Information]
Waldman, B., Jenkins, A., Davis, T., Taskinen, M., Scott, R., O'Connell, R., Gebski, V., Ng, M., Keech, A. (2014). HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. Diabetes Care, 37(8), 2351-2358. [More Information]
Ding, L., Cheng, R., Hu, Y., Takahashi, Y., Jenkins, A., Keech, A., Humphries, K., Gu, X., Elliott, M., Xia, X., et al (2014). Peroxisome Proliferator-Activated Receptor alpha Protects Capillary Pericytes in the Retina. American Journal of Pathology, 184(10), 2709-2720. [More Information]
Chan, K., Simpson, P., Yong, A., Dunn, L., Chawantanpipat, C., Hsu, C., Yu, Y., Keech, A., Celermajer, D., Ng, M. (2014). The Relationship between Endothelial Progenitor Cell Populations and Epicardial and Microvascular Coronary Disease-A Cellular, Angiographic and Physiologic Study. PloS One, 9(4), 1-12. [More Information]
Boekholdt, S., Hovingh, G., Mora, S., Arsenault, B., Amarenco, P., Pedersen, T., LaRosa, J., Waters, D., DeMicco, D., Simes, R., Keech, A., et al (2014). Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. Journal of the American College of Cardiology, 64(5), 485-494. [More Information]
Sullivan, T., Duque, G., Keech, A., Herrmann, M. (2013). An Old Friend in a New Light: The Role of Osteocalcin in Energy Metabolism. Cardiovascular Therapeutics (Online), 31(2), 65-75. [More Information]
Noonan, J., Jenkins, A., Ma, J., Keech, A., Wang, J., Lamoureux, E. (2013). An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes. Diabetes, 62(12), 3968-3975. [More Information]
Ghosh, J., Martin, A., Keech, A., Chan, K., Gomes, S., Singarayar, S., McGuire, M. (2013). Balloon Warming Time Is the Strongest Predictor Of Late Pulmonary Vein Electrical Reconnection Following Balloon Cryoablation for Atrial Fibrillation. Heart Rhythm, 10(9), 1311-1317. [More Information]
White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, I., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
Ting, R., Keech, A. (2013). Fenofibrate and renal disease: Clinical effects in diabetes. Clinical Lipidology, 8(6), 669-680. [More Information]
Simo, R., Roy, S., Behar-Cohen, F., Keech, A., Mitchell, P., Wong, T. (2013). Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Current Medicinal Chemistry, 20(26), 3258-3266. [More Information]
Olver, I., Keech, A. (2013). Forming networks for research: proposal for an Australian clinical trials alliance. Medical Journal of Australia, 198(5), 254-255. [More Information]
Dignan, R., Keech, A., Gebski, V., Robledo, K., Hughes, C. (2013). Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. International Journal of Cardiology, 168(6), 5378-5384. [More Information]
Chan, K., O'Connell, R., Sullivan, D., Hoffmann, L., Rajamani, K., Whiting, M., Donoghoe, M., Vanhala, M., Hamer, A., Yu, B., Stocker, R., Ng, M., Keech, A. (2013). Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (field) study. Diabetologia, 56(4), 724-736. [More Information]
Hankey, G., Anderson, N., Ting, R., Veillard, A., Romo, M., Wosik, M., Sullivan, D., O'Connell, R., Hunt, D., Keech, A. (2013). Rates and predictors of risk of stroke and its subtypes in diabetes: A prospective observational study. Journal of Neurology, Neurosurgery and Psychiatry, 84(3), 281-287. [More Information]
Chen, Y., Hu, Y., Lin, M., Jenkins, A., Keech, A., Mott, R., Lyons, T., Ma, J. (2013). Therapeutic Effects of PPARÎ± Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. Diabetes, 62(1), 261-272. [More Information]
Ting, R., Keech, A., Drury, P., Donoghoe, M., Hedley, J., Jenkins, A., Davis, T., Lehto, S., Celermajer, D., Simes, R., Rajamani, K., et al (2012). Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment - The FIELD Study. Diabetes Care, 35(2), 218-225. [More Information]
Tonkin, A., Hunt, D., Voysey, M., Kesaniemi, Y., Hamer, A., Waites, J., Mahar, L., Mann, S., Glasziou, P., Forder, P., Simes, R., Keech, A. (2012). Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. American Heart Journal, 163(3), 508-514. [More Information]
Jun, M., Zhu, B., Tonelli, M., Jardine, M., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., Perkovic, V. (2012). Effects of Fibrates in Kidney Disease: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 60(20), 2061-2071. [More Information]
Best, J., Drury, P., Davis, T., Taskinen, M., Kesaniemi, Y., Scott, R., Pardy, C., Voysey, M., Keech, A. (2012). Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort. Diabetes Care, 35(5), 1165-1170. [More Information]
Emberson, J., Kearney, P., Blackwell, L., Newman, C., Reith, C., Bhala, N., Holland, L., Peto, R., Keech, A., Collins, R., Simes, R., et al (2012). Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175 000 people in 27 randomised trials of statin therapy. PloS One, 7(1), 1-10. [More Information]
Preiss, D., Tikkanen, M., Welsh, P., Ford, I., Lovato, L., Elam, M., laRosa, J., DeMicco, D., Colhoun, H., Goldenberg, I., Keech, A., et al (2012). Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis. JAMA, 308(8), 804-811. [More Information]
Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
Herrmann, M., Whiting, M., Veillard, A., Ehnholm, C., Sullivan, D., Keech, A. (2012). Plasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD study. Clinical Chemistry and Laboratory Medicine, 50(12), 2213-2219. [More Information]
Mihaylova, B., Emberson, J., Keech, A., Collins, R., Baigent, C. (2012). Statins for people at low risk of cardiovascular disease - Authors' reply. The Lancet, 380(9856), 1817-1818. [More Information]
Fulcher, J., Keech, A. (2012). The case for more intensive use of statins. Therapeutic Advances in Chronic Diseases, 3(5), 201-210. [More Information]
Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, R., Barnes, E., Voysey, M., Gray, A., Collins, R., Baigent, C., et al (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590. [More Information]
Ng, M., Yong, A., Ho, M., Shah, M., Chawantanpipat, C., O'Connell, R., Keech, A., Kritharides, L., Fearon, W. (2012). The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 5(4), 515-522. [More Information]
Keech, A., Simes, R., Fulcher, J. (2012). The role of statin therapy in patients with lower vascular risk. Medical Journal of Australia, 197(3), 130-131. [More Information]
Sullivan, D., Forder, P., Simes, R., Whiting, M., Kritharides, L., Merrifield, A., Donoghoe, M., Colman, P., Neil, G., Haapamaki, H., Keech, A. (2011). Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 94(2), 284-290. [More Information]
Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
Drury, P., Ting, R., Zannino, D., Ehnholm, C., Flack, J., Whiting, M., Fassett, R., Ansquer, J., Dixon, P., Davis, T., Pardy, C., Keech, A., et al (2011). Estimated Glomerular Filtration Rate and Albuminuria are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(1), 32-43. [More Information]
Scott, R., Donoghoe, M., Watts, G., O'Brien, R., Pardy, C., Taskinen, M., Davis, T., Colman, P., Manning, P., Fulcher, G., Keech, A. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10(1), 102-1-102-8. [More Information]
Hayes, A., Clarke, P., Voysey, M., Keech, A. (2011). Simulation of Quality-Adjusted Survival in Chronic Diseases: An Application in Type 2 Diabetes. Medical Decision Making, 31(4), 559-570. [More Information]
Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PloS One, 5(1), e8580-1-e8580-10. [More Information]
Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Robledo, K., Simes, R., Best, J., Hamwood, S., Keech, A. (2010). Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 53(9), 1846-1855. [More Information]
Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., Keech, A., Simes, R., et al (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. [More Information]
Burgess, D., Hunt, D., Li, L., Zannino, D., Williamson, E., Davis, T., Laakso, M., Kesaniemi, Y., Zhang, J., Sy, R., Keech, A., et al (2010). Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. European Heart Journal, 31(1), 92-99. [More Information]
Chan, K., Chawantanpipat, C., Gattorna, T., Chantadansuwan, T., Kirby, A., Madden, A., Keech, A., Ng, M. (2010). The relationship between coronary stenosis severity and compression type coronary artery movement in acute myocardial infarction. American Heart Journal, 159(4), 584-592. [More Information]
Keech, A., Horowitz, J. (2009). Cost-effectiveness Considerations of Cardiovascular Therapeutics. Heart, Lung, and Circulation, 18(2), 118-122. [More Information]
Rajamani, K., Coleman, P., Li, L., Best, J., Voysey, M., D'Emden, M., Laakso, M., Baker, J., Keech, A., FIELD study investigators, F. (2009). Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. The Lancet, 373(9677), 1780-1788. [More Information]
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Boey (Tse), D., Taskinen, M., Ehnholm, C., Keech, A., FIELD study investigators, F. (2009). Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 32(3), 493-498. [More Information]
Soderberg, S., Colquhoun, D., Keech, A., Yallop, J., Barnes, E., Pollicino, C., Simes, R., Tonkin, A., Nestel, P. (2009). Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity, 33(1), 123-130. [More Information]
Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009). Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 950-955. [More Information]
Clarke, P., Hayes, A., Glasziou, P., Scott, R., Simes, R., Keech, A. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61-68. [More Information]
Hayes, A., Clarke, P., Glasziou, P., Simes, R., Drury, P., Keech, A. (2008). Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care, 31(4), 795-797. [More Information]
Kearney, P., Blackwell, L., Collins, R., Keech, A., Simes, R., Peto, R., Armitage, J., Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet, 371, 117-125. [More Information]
Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - author's reply. The Lancet, 371, 722.
Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - Authors' reply. The Lancet, 371(9614), 722-722. [More Information]
Keech, A., Mitchell, P. (2008). FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy. Review of Endocrinology.
Hiukka, A., Westerbacka, J., Leinonen, E., Watanabe, H., Wiklund, O., Hulten, L., Salonen, J., Tuomainen, T., Yki-Jarvinen, H., Keech, A., et al (2008). Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. Journal of the American College of Cardiology, 52(25), 2190-2197. [More Information]
Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008). Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry, 54(6), 1038-1045. [More Information]
Kearney, P., Keech, A., Simes, R., Collins, R. (2008). Statins and diabetes: authors' reply. The Lancet, 371(9626), 1752-1752.
Scott, R., D'Emden, M., Best, J., Drury, P., Ehnholm, C., Kesaniemi, Y., Pardy, C., Tse, D., Barter, P., Taskinen, M., Copt, S., Keech, A., et al (2007). Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate. Circulation, 116, II_838.
Marschner, I., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
Davis, W., Davis, T., Keech, A. (2007). Calculating cardiovascular risk in people with diabetes. Diabetes Management Journal, 18(March), 32-32.
Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
Keech, A., Pike, R., Granger, R., Gebski, V. (2007). Interpreting the results of a clinical trial. Medical Journal of Australia, 186(9), 318-319. [More Information]
Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A., Taskinen, M. (2007). Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia, 50(10), 2067-2075. [More Information]
Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. Medical Journal of Australia, 186(7), 368-370. [More Information]
Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.
Keech, A., Simes, R. (2006). Clinical trial design & management: The role of PPAR-ALPHA agonists in prevention of CVD. Atherosclerosis Supplements, 7(3), 174-174.
Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). Correction to the FIELD study report. The Lancet, 368(9545), 1415. [More Information]
Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment - Reply. The Lancet, 367(9509), 470-471.
Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment-authors' reply [letter]. The Lancet, 367(9509), 470-471. [More Information]
Alexander, K., Newby, L., Bhapkar, M., White, H., Hochman, J., Pfisterer, M., Moliterno, D., Peterson, E., Van de Werf, F., Simes, R., Keech, A., et al (2006). International variation in invasive care of the elderly with acute coronary syndromes. European Heart Journal, 27(13), 1558-1564. [More Information]
Burgess, D., Kilborn, M., Keech, A. (2006). Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. European Heart Journal, 27(23), 2846-2857. [More Information]
Grieve, S., Ansquer, J., Keech, A. (2006). Micronized fenofibrate: A useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology, 2(6), 635-646. [More Information]
Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. Journal of the National Cancer Institute, 98(17), 1021-1022. [More Information]
Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. Journal of the National Cancer Institute, 98(1), 26-38. [More Information]
Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). The FIELD study - Reply. The Lancet, 367(9517), 1142-1143. [More Information]
Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding [reply]. Medical Journal of Australia, 183(3), 165-166.
Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding: when ignorance is bliss. Medical Journal of Australia, 182(2), 87-89. [More Information]
McAvoy, B., Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., Neale, M., Pollock, C., et al (2005). An evidence based clinical aid for cardiovascular disease--what do GPs think? Australian Family Physician, 34(4), 297-298. [More Information]
Briffa, T., Eckermann, S., Griffiths, A., Harris, P., Heath, M., Freedman, B., Donaldson, L., Briffa, N., Keech, A. (2005). Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Medical Journal of Australia, 183(9), 450-455. [More Information]
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with chronic kidney disease and diabetes mellitus. Hypertension, 46(4), 900-901.
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology, 16(12), 3748-3754. [More Information]
Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M., Forder, P., Pillai, A., Davis, T., Glasziou, P., Sullivan, D., MacMahon, S., et al (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849-1861. [More Information]
Baigent, C., Keech, A., Kearney, P., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267-1278. [More Information]
Scott, R., Best, J., Forder, P., Taskinen, M., Simes, R., Barter, P., Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovascular Diabetology, 4(13), 1-9. [More Information]
Lundman, P., Keech, A., Griffiths, K., Pillai, A., Celermajer, D. (2005). New carotid plaque formation is very common in adult patients with Type 2 diabetes mellitus. Diabetic Medicine, 22(3), 355-356. [More Information]
Keech, A., Grieve, S., Patel, A., Griffiths, K., Skilton, M., Watts, G., Marwick, T., Groshens, M., Celermajer, D. (2005). Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. Diabetic Medicine, 22(11), 1558-1565. [More Information]
Keech, A., Wonders, S., Cook, D., Gebski, V. (2004). Balancing the outcomes: reporting adverse events. Medical Journal of Australia, 181(4), 215-218.
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. The Lancet, 363(9411), 757-767. [More Information]
Colquhoun, D., Keech, A., Hunt, D., Marschner, I., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
Seale, J., Gebski, V., Keech, A. (2004). Generalising the results of trials to clinical practice. Medical Journal of Australia, 181(10), 558-560. [More Information]
O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.
Lord, S., Gebski, V., Keech, A. (2004). Multiple Analyses In Clinical Trials: Sound Science Or Data Dredging? Medical Journal of Australia, 181(8), 452-454.
Keech, A., Best, J., Scott, R., Barter, P., Simes, R., Forder, P., Taskinen, M., FIELD study investigators, F. (2004). Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes. Journal of the American College of Cardiology, 43(5), A462-A462.
Cook, D., Gebski, V., Keech, A. (2004). Subgroup analysis in clinical trials. Medical Journal of Australia, 180(6), 289-291.
Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]
Barter, P., Best, J., Coleman, P., D'Emden, M., Davis, T., Drury, P., Ehnholm, C., Keech, A., Simes, R., et al (2004). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology, 3(December), 9 - 1-9 - 11. [More Information]
Sniderman, A., Furberg, C., Keech, A., Roeters van Lennep, J., Frohlich, J., Jungner, I., Walldius, G. (2003). Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. The Lancet, 361(9359), 777-780. [More Information]
Burgess, D., Gebski, V., Keech, A. (2003). Baseline data in clinical trials. Medical Journal of Australia, 11, 105-107.
Pike, R., Keech, A., Simes, R. (2003). Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002. Medical Journal of Australia, 178(7), 316-317.
Kirby, A., Gebski, V., Keech, A. (2003). Determining the sample size in a clinical trial [in reply]. Medical Journal of Australia, 178(7), 358-358. [More Information]
Vachan, B., Gebski, V., Keech, A. (2003). Flow of participants in randomised studies. Medical Journal of Australia, 178, 347-349.
Heritier, S., Gebski, V., Keech, A. (2003). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Medical Journal of Australia, 11, 438-440.
Keech, A., Gebski, V. (2003). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects. Medical Journal of Australia, 178(7), 356-357.
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., et al (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet, 361(9374), 2005-2016. [More Information]
Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., McAvoy, B., Neale, M., Pollock, C., et al (2003). Prevention of cardiovascular disease: an evidence-based clinical aid. MJA Focus, (21 July 2003), 1-14.
Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721. [More Information]
Gebski, V., Keech, A. (2003). Statistical methods in clinical trials. Medical Journal of Australia, 11, 182-184.
Kilian, J., Keech, A., Adams, M., Celermajer, D. (2002). Coronary collateralization: determinants of adequate distal vessel filling after arterial occlusion. Coronary Artery Disease, 13(3), 155-159. [More Information]
Sacks, F., Tonkin, A., Craven, T., Pfeffer, M., Shepherd, J., Keech, A., Furberg, C., Braunwald, E. (2002). Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105(12), 1424-1428.
Kirby, A., Gebski, V., Keech, A. (2002). Determining the sample size in a clinical trial. Medical Journal of Australia, 177(5), 256-257.
Neal, B., MacMahon, S., Ohkubo, T., Tonkin, A., Wilcken, D., Keech, A. (2002). Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. European Heart Journal, 23(19), 1509-1515. [More Information]
Simes, R., Furberg, C., Braunwald, E., Davis, B., Ford, I., Tonkin, A., Shepherd, J., Keech, A. (2002). Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. European Heart Journal, 23(3), 207-215. [More Information]
Keech, A., Neal, B., MacMahon, S., Ohkubo, T., Brnabic, A., Tonkin, A. (2002). Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. Journal Of The Renin-Angiotensin-Aldosterone System, 3(4), 270-276. [More Information]
Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387. [More Information]
Keech, A., Gebski, V. (2002). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? Medical Journal of Australia, 177(8), 437-439.
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360, 23-33. [More Information]
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360(9326, 6 July 2002), 7-22. [More Information]
Beller, E., Gebski, V., Keech, A. (2002). Randomisation in clinical trials. Medical Journal of Australia, 177(10), 565-567. [More Information]
Simes, R., Keech, A., et al (2002). Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 105(3), 316-321.
Simes, R., Marschner, I., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169. [More Information]
Richie, G., Keech, A., Yamamoto,, A., Nakamura, H., Hosoda,, S., Nobuyoshi,, M., Matsuzaki, M., Tan, C., Mabuchi, H., Horibe, H., et al (2002). Risk factors for coronary heart disease in the Japanese - Comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Journal of Atherosclerosis and Thrombosis, 9(4), 191-199.
Pfeffer, M., Keech, A., Sacks, F., Cobbe, S., Tonkin, A., Byington, R., Davis, B., Friedman, C., Braunwald, E. (2002). Safety and tolerability of pravastatin in long-term clinical trials. Circulation, 105(20), 2341-2346. [More Information]
Brighton, J., Gebski, V., Keech, A. (2002). Specifying interventions in a clinical trial. Medical Journal of Australia, 176(6), 281-282. [More Information]
Gebski, V., Marschner, I., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492. [More Information]
Ritchie, G., Keech, A. (2001). Asia-Pacific collaboration on coronary heart disease risk factor intervention: study desing and methods. Heart, Lung, and Circulation, 10, 24-29. [More Information]
Hughes, C., Keech, A., Cox,, N. (2001). Myocardial infarction due to saphenous vein graft compression by an extracardiac mass. Heart, Lung, and Circulation, 10, 35-37.
Gebski, V., Beller, E., Keech, A. (2001). Randomized controlled trails: elements of a good study. Medical Journal of Australia, 175, 272-274.
Ghersi, D., Gebski, V., Keech, A. (2001). Scientific background and rationale for a randomised controlled trial. Medical Journal of Australia, 175(7), 386-386. [More Information]
Keech, A., Gebski, V. (2001). Selecting participants for clinical trials. Medical Journal of Australia, 175(9), 490-491. [More Information]
Miller, O., Tang, S., Keech, A., Pigott, N., Beller, E., Celermajer, D. (2000). Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. The Lancet, 356(9240), 1464-1469. [More Information]

show 280 more

Conferences

Keech, A. (2006). Challenges in undertaking primary prevention trials. 54th Annual Scientific Meeting of the Cardiac Society of Australian and New Zealand.
Keech, A. (2006). Effects of long-term fenofibrate therapy in the FIELD study. Meeting of the Taiwan Endocrine Society.
Keech, A. (2006). Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The FIELD study, a randomised controlled trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Keech, A., Best, J. (2006). Highlights from the FIELD trial: a landmark trial. Annual Scientific Sessions of the American Diabetes Association.
Sullivan, D., Forder, P., Simes, R., Whiting, M., Keech, A. (2006). Individual and combined effects of fenofibrate and sulphonylureas on HDL cholesterol and outcomes. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Keech, A. (2006). Issues in clinical trial design and management: example of the role of PPAR-alpha agonists in prevention of CVD, satellite symposium. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Keech, A. (2006). Metabolic syndrome and diabetes. NHLBI National Cholesterol Education Program (USA).
Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Hiukka, A., Leinonen, E., Hilden, H., Perttunen-Nio, H., Keech, A., Taskinen, M. (2006). Reduction of large VLDL particles by fenofibrate is associated with reduction of small dense LDL in type 2 diabetes: Field Helsinki substudy. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Keech, A. (2006). Role of PPAR-alpha agonists in diabetic disease. Metabolic Syndrome Institute Meeting.
Keech, A. (2006). To manage diabetes: management in the early stages. Solvay Scientific Meeting.
Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
Keech, A. (2005). Developing evidence-based practice in Diabetes care: FIELD, a Landmark Trial. American Diabetes Association 2005.
Keech, A. (2005). FIELD study: a large scale trial of fibrate therapy in diabetes. ASEAN Federation of Endocrine Societies.
Keech, A. (2005). The long-term efficacy and safety of Fenofibrate therapy to prevent cardiovascular events in 9795 people with type 2 diabetes mellitus: the main results of the FIELD study. American Heart Association Annual Scientific Sessions.
Keech, A. (2004). Effects of fenofibrate on lipid parameters in Type 2 Diabetes: a large-scale trial to prevent cardiovascular disease. 40th Annual Meeting of the EASD.
Keech, A. (2004). Rationale for a large-scale trial of fenofibrate to prevent cardiovascular disease in Type 2 Diabetes. Fournier Symposium; Taiwan Endocrinology & Diabetes Association Meeting.
Keech, A. (2004). Significant lipid changes with fenofibrate in Type 2 Diabetes in a large-scale trial to prevent cardiovascular disease. APSAVD Meeting.
Keech, A. (2003). Logistics of large scale studies in diabetes and vascular studies â€“ FIELD & HPS. Australian Nurses Cardiovascular & Hypertension Association.
Keech, A. (2003). The Heart Protection Study: Results and clinical implications for treatment of patients in the Asia-Pacific and international lipid guidelines. International Atherosclerosis Society.
Keech, A. (2003). The link between Chronic Inflammation, Obesity and Endothelial Dysfunction. Cardiac Society of Australia & New Zealand.
Keech, A. (2002). An update on clinical trials in diabetes. Australian Diabetes Society.
Keech, A. (2002). Approaches to the patient with metabolic syndrome. ASEANZ 2002.
Keech, A. (2002). Challenges in the prevention of atherosclerosis in the Asia-Pacific region. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
Keech, A. (2002). Clinical Trials: drug or class effects? 14th ASEAN Congress of Cardiology.
Keech, A. (2002). Evidence-based clinical practice in diabetes. European Association of Diabetes Societies.
Keech, A. (2002). HDL cholesterol: a new therapeutic target for CHD prevention. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
Keech, A. (2002). New insights from the Heart Protection Study. Asian Congress of Cardiology. Asian Congress of Cardiology.
Keech, A. (2002). Principles of prospective meta-analysis. Clinical Trials Symposium.
Keech, A. (2002). Rationale, results and implications of the Heart Protection Study. Malaysian Medical Society Meeting.
Keech, A. (2002). Recent advances in clinical trials for treatment of atherosclerosis in diabetes. Australian Health & Medical Research Congress 2002.

show 29 more

Report

Keech, A. (2004). PBAC review of eligibility criteria for lipid lowering drugs.

Expand all

2024

Burns, B., Marschner, I., Eggins, R., Buscher, H., Morton, R., Bendall, J., Keech, A., Dennis, M. (2024). A randomized trial of expedited intra-arrest transfer versus more extended on-scene resuscitation for refractory out of hospital cardiac arrest: Rationale and design of the EVIDENCE trial. American Heart Journal, 267, 22-32. [More Information]
Tucker, W., Tucker, B., Januszewski, A., Jenkins, A., Keech, A., Kestenbaum, B., Allison, M., Rye, K., Ong, K. (2024). Association of circulating fibroblast growth factor 21 levels with all-cause and cardiovascular mortality: The multi-ethnic study of atherosclerosis. Clinica Chimica Acta, 555, 117799. [More Information]
Tucker, B., Goonetilleke, N., Patel, S., Keech, A. (2024). Colchicine in atherosclerotic cardiovascular disease. Heart, 110(9), 618-625. [More Information]
Januszewski, A., Young, H., Ong, K., Li, L., O'Connell, R., Lyons, T., Kelly, C., Zaharieva, D., Sullivan, D., Scott, R., Keech, A., Jenkins, A. (2024). Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate. Journal of Diabetes Investigation. [More Information]
Rehan, R., Ng, M., Virk, S., Wong, C., Passam, F., Layland, J., Keech, A., Yong, A., White, H., Fearon, W. (2024). Intracoronary thrombolysis in ST-elevation myocardial infarction: A systematic review and meta-analysis. Heart, , heartjnl-2024-324078. [More Information]
Mihaylova, B., Wu, R., Zhou, J., Williams, C., Schlackow, I., Emberson, J., Reith, C., Keech, A., Robson, J., Simes, R. (2024). Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study. The Lancet Regional Health. Europe, 40, 100887. [More Information]
Mihaylova, B., Armitage, J., Gray, A., Simes, J., Baigent, C., Wu, R., Zhou, J., Williams, C., Schlackow, I., Emberson, J., Keech, A., et al (2024). Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study. Heart. [More Information]
Wu, R., Gray, A., Simes, R., Baigent, C., Mihaylova, B., Williams, C., Zhou, J., Schlackow, I., Emberson, J., Reith, C., Keech, A., et al (2024). Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model. British Journal of General Practice, 74(740), e189-e198. [More Information]
McClintick, D., Monsalvo, M., Atar, D., Keech, A., Giugliano, R., Sabatine, M., O'Donoghue, M., De Ferrari, G., Ferreira, J., Ran, X., et al (2024). Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. Journal of the American College of Cardiology, 83(6), 652-664. [More Information]
Jenkins, A., O'Connell, R., Januszewski, A., Webster, A., Davis, T., Jardine, M., Scott, R., Taskinen, M., Keech, A. (2024). Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes. Diabetes Research and Clinical Practice, 210, 111612-111612. [More Information]

show 7 more

2023

Sheu, A., O'Connell, R., Jenkins, A., Tran, T., Drury, P., Sullivan, D., Li, L., Colman, P., O’Brien, R., Kesäniemi, Y., Keech, A., et al (2023). Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes - Metabolism: Research and Reviews. [More Information]
Smith, G., Abraham, M., de Bock, M., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., et al (2023). Impact of Missing Data on the Accuracy of Glucose Metrics from Continuous Glucose Monitoring Assessed Over a 2-Week Period. Diabetes Technology and Therapeutics, 25(5), 356-362. [More Information]
O'Rourke, M., Januszewski, A., Sullivan, D., Lengyel, I., Stewart, A., Arya, S., Ma, R., Galande, S., Hardikar, A., Joglekar, M., Keech, A., Jenkins, A., Molloy, M. (2023). Optimised plasma sample preparation and LC-MS analysis to support large-scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial. Proteomics - Clinical Applications. [More Information]
Zhou, J., Wu, R., Williams, C., Emberson, J., Reith, C., Keech, A., Robson, J., Armitage, J., Gray, A., Simes, R., et al (2023). Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK. PharmacoEconomics, 41(5), 547-559. [More Information]
Brazionis, L., Quinn, N., Dabbah, S., Ryan, C., Møller, D., Richardson, H., Keech, A., Januszewski, A., Grauslund, J., Rasmussen, M., Jenkins, A., et al (2023). Review and comparison of retinal vessel calibre and geometry software and their application to diabetes, cardiovascular disease, and dementia. Graefe's Archive for Clinical and Experimental Ophthalmology. [More Information]

show 2 more

2022

Stewart, R., Kirby, A., White, H., Marschner, S., West, M., Thompson, P., Sullivan, D., Janus, E., Hunt, D., Kritharides, L., Keech, A., Simes, R., et al (2022). B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease. Journal of the American Heart Association, 11(13). [More Information]
Fagundes, A., Morrow, D., Oyama, K., Furtado, R., Zelniker, T., Tang, M., Kuder, J., Murphy, S., Hamer, A., Keech, A., et al (2022). Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. Journal of the American College of Cardiology, 80(9), 887-897. [More Information]
Trawley, S., Stephens, A., McAuley, S., Speight, J., Hendrieckx, C., Vogrin, S., Lee, M., Paldus, B., Bach, L., Burt, M., Holmes-Walker, J., Keech, A., et al (2022). Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 24(5), 350-356. [More Information]
Furtado, R., Fagundes, A., Oyama, K., Zelniker, T., Tang, M., Kuder, J., Murphy, S., Hamer, A., Wang, H., Keech, A., et al (2022). Effect of Evolocumab in Patients with Prior Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 15(3), 227-236. [More Information]
Robledo, K., Tarnow-Mordi, W., Rieger, I., Suresh, P., Martin, A., Yeung, C., Ghadge, A., Liley, H., Osborn, D., Morris, J., Hague, W., Kluckow, M., Keech, A., Kirby, A., Simes, R., et al (2022). Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trial. The Lancet Child and Adolescent Health, 6(3), 150-157. [More Information]
Tran, D., Gibson, H., Maiorana, A., Verrall, C., Baker, D., Clode, M., Lubans, D., Zannino, D., Bullock, A., Ferrie, S., Gosbell, S., Davis, G., Keech, A., Puranik, R., Majumdar, A., Ayer, J., Celermajer, D., Cordina, R., et al (2022). Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)—Rationale and Design. Frontiers in Pediatrics, 9, 799125. [More Information]
Quinn, N., Januszewski, A., Brazionis, L., O'Connell, R., Aryal, N., O'Day, J., Scott, R., Mitchell, P., Jenkins, A., Keech, A. (2022). Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy. Internal Medicine Journal, 52(4), 676-679. [More Information]
Drak, D., Fulcher, J., Kilian, J., Chong, J., Grover, R., Sindone, A., Adams, M., Lattimore, J., Keech, A. (2022). Guideline-based audit of the hospital management of heart failure with reduced ejection fraction. Internal Medicine Journal. [More Information]
Roberts, A., Fried, L., Dart, J., De Bock, M., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., et al (2022). Hybrid closed-loop therapy with a first-generation system increases confidence and independence in diabetes management in youth with type 1 diabetes. Diabetic Medicine, 39(9). [More Information]
O'Donoghue, M., Giugliano, R., Wiviott, S., Atar, D., Keech, A., Kuder, J., Im, K., Murphy, S., Flores-Arredondo, J., López, J., et al (2022). Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 146(15), 1109-1119. [More Information]
Korthauer, L., Giugliano, R., Guo, J., Sabatine, M., Sever, P., Keech, A., Atar, D., Kurtz, C., Ruff, C., Mach, F., et al (2022). No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PloS One, 17(2023-04-04 00:00:00). [More Information]
Atkinson-Briggs, S., Ryan, C., Keech, A., Jenkins, A., Brazionis, L. (2022). Nurse-led vascular risk assessment in a regional Victorian Indigenous primary care diabetes clinic: An integrated Diabetes Education and Eye disease Screening [iDEES] study. Journal of Advanced Nursing, 78(11), 3652-3661. [More Information]
Cheng, F., Luk, A., Wu, H., Tam, C., Lim, C., Fan, B., Jiang, G., Carroll, L., Yang, A., Lau, E., Keech, A., Joglekar, M., Hardikar, A., Jenkins, A., Ma, R., et al (2022). Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register. Diabetologia, 65(2), 375-386. [More Information]
Rao, B., Quinn, N., Januszewski, A., Peto, T., Brazionis, L., Aryal, N., O'Connell, R., Li, L., Summanen, P., Scott, R., Keech, A., Jenkins, A., et al (2022). Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Research and Clinical Practice, 186, 109835-1-109835-6. [More Information]
Cheng, F., Luk, A., Shi, M., Huang, C., Jiang, G., Yang, A., Wu, H., Lim, C., Tam, C., Fan, B., Carroll, L., Keech, A., Joglekar, M., Hardikar, A., Jenkins, A., et al (2022). Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. Diabetes Care, 45(3), 701-709. [More Information]
Abraham, M., Smith, G., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., de Bock, M., et al (2022). Snapshot of CGM Metrics in Adolescents and Adults Achieving Target HbA1c Versus Those Not Meeting Target HbA1c. Diabetes Technology and Therapeutics, 24(9), 677-679. [More Information]

show 13 more

2021

Atkinson-Briggs, S., Jenkins, A., Keech, A., Ryan, C., Brazionis, L. (2021). A model of culturally-informed integrated diabetes education and eye screening in indigenous primary care services and specialist diabetes clinics: Study protocol. Journal of Advanced Nursing, 77(3), 1578-1590. [More Information]
Brazionis, L., Keech, A., Ryan, C., Brown, A., O'Neal, D., Boffa, J., Bursell, S., Jenkins, A. (2021). Associations with sight-threatening diabetic macular oedema among Indigenous adults with type 2 diabetes attending an Indigenous primary care clinic in remote Australia: A Centre of Research Excellence in Diabetic Retinopathy and Telehealth Eye and Associated Medical Services Network study. BMJ Open Ophthalmology, 6(1), e000559. [More Information]
Marston, N., Giugliano, R., Park, J., Ruzza, A., Sever, P., Keech, A., Sabatine, M. (2021). Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl. Circulation, 144(21), 1732-1734. [More Information]
Marston, N., Patel, P., Kamanu, F., Nordio, F., Melloni, G., Roselli, C., Gurmu, Y., Weng, L., Bonaca, M., Giugliano, R., Keech, A., et al (2021). Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. Circulation, 143(5), 470-478. [More Information]
Marston, N., Oyama, K., Jarolim, P., Tang, M., Sever, P., Keech, A., Pineda, A., Wang, H., Giugliano, R., Sabatine, M., et al (2021). Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation, 144(3), 249-251. [More Information]
Abraham, M., De Bock, M., Smith, G., Dart, J., Fairchild, J., King, B., Ambler, G., Cameron, F., McAuley, S., Keech, A., Jenkins, A., et al (2021). Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents with Type 1 Diabetes: A Randomized Clinical Trial. JAMA Pediatrics, 175(12), 1227-1235. [More Information]
Oyama, K., Giugliano, R., Tang, M., Bonaca, M., Saver, J., Murphy, S., Ruzza, A., Keech, A., Sever, P., Sabatine, M., et al (2021). Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. European Heart Journal, 42(47), 4821-4829. [More Information]
Oyama, K., Furtado, R., Fagundes, A., Zelniker, T., Tang, M., Kuder, J., Murphy, S., Hamer, A., Wang, H., Keech, A., et al (2021). Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. Journal of the American College of Cardiology, 77(3), 259-267. [More Information]
Keech, A., Oyama, K., Sever, P., Tang, M., Murphy, S., Hirayama, A., Lu, C., Tay, L., Deedwania, P., Siu, C., et al (2021). Efficacy and safety of long-term evolocumab use among Asian subjects - A subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (fourier) trial - A s. Circulation Journal, 85(11), 2063-2070. [More Information]
Fiolet, A., Opstal, T., Mosterd, A., Eikelboom, J., Jolly, S., Keech, A., Kelly, P., Tong, D., Layland, J., Thompson, P., et al (2021). Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal, 42(28), 2765-2775. [More Information]
Deedwania, P., Murphy, S., Scheen, A., Badariene, J., Pineda, A., Honarpour, N., Keech, A., Sever, P., Pedersen, T., Sabatine, M., et al (2021). Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: Secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiology, 6(2), 139-147. [More Information]
Marston, N., Melloni, G., Gurmu, Y., Bonaca, M., Kamanu, F., Roselli, C., Lee, C., Cavallari, I., Giugliano, R., Scirica, B., Keech, A., et al (2021). Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation. Genomic and Precision Medicine, 14(1), e003006. [More Information]
Januszewski, A., Cho, Y., Joglekar, M., Farr, R., Scott, E., Wong, W., Carroll, L., Loh, Y., Benitez-Aguirre, P., Keech, A., Craig, M., Hardikar, A., Donaghue, K., Jenkins, A., et al (2021). Insulin micro-secretion in Type 1 diabetes and related microRNA profiles. Scientific Reports, 11(1), 11727. [More Information]
Sever, P., Gouni-Berthold, I., Keech, A., Giugliano, R., Pedersen, T., Im, K., Wang, H., Knusel, B., Sabatine, M., O’Donoghue, M. (2021). LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. European Journal of Preventive Cardiology, 28, 805-812. [More Information]
McAuley, S., Vogrin, S., Lee, M., Paldus, B., Trawley, S., De Bock, M., Abraham, M., Bach, L., Burt, M., Cohen, N., Jenkins, A., Keech, A., et al (2021). Less Nocturnal Hypoglycemia but Equivalent Time in Range among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 23(6), 460-466. [More Information]
Lu, J., Vogrin, S., McAuley, S., Lee, M., Paldus, B., Bach, L., Burt, M., Clarke, P., Cohen, N., Colman, P., Holmes-Walker, J., Jenkins, A., Keech, A., O'Neal, D., et al (2021). Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 179, 109000. [More Information]
Atar, D., Jukema, J., Molemans, B., Taub, P., Goto, S., Mach, F., CerezoOlmos, C., Underberg, J., Keech, A., Tokgozoglu, L., et al (2021). New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis, 319, 51-61. [More Information]
Snir, A., Wilson, M., Ju, L., Zhao, Y., Wong, S., Khor, L., Naoum, C., Wong, K., Keech, A., Celermajer, D., Ng, M. (2021). Novel Pressure-Regulated Deployment Strategy for Improving the Safety and Efficacy of Balloon-Expandable Transcatheter Aortic Valves. J A C C: Cardiovascular Interventions, 14(22), 2503-2515. [More Information]
Atkinson-Briggs, S., Jenkins, A., Keech, A., Ryan, C., Brazionis, L. (2021). Prevalence of diabetic retinopathy and reduced vision among indigenous Australians in the nurse-led integrated Diabetes Education and Eye Screening study in a regional primary care clinic. Internal Medicine Journal. [More Information]
Bubb, K., Harmer, J., Finemore, M., Aitken, S., Ali, Z., Billot, L., Chow, C., Golledge, J., Mister, R., Gray, M., Grieve, S., Keech, A., Patel, S., Figtree, G., et al (2021). Protocol for the Stimulating β3- Adrenergic Receptors for Peripheral Artery Disease (STAR- PAD) trial: a double- blinded, randomised, placebo- controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease. BMJ Open, 11(9), e049858-1-e049858-10. [More Information]
Januszewski, A., Chen, D., Scott, R., O'Connell, R., Aryal, N., Sullivan, D., Watts, G., Taskinen, M., Barter, P., Best, J., Simes, R., Keech, A., Jenkins, A. (2021). Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 11(1), 18708. [More Information]
Quinn, N., Yang, F., Ryan, C., Bursell, S., Keech, A., Atkinson-Briggs, S., Jenkins, A., Brazionis, L. (2021). Screening for Diabetic Retinopathy and Reduced Vision among Indigenous Australians in Top End Primary Care Health Services: a TEAMSnet Sub-study. Internal Medicine Journal, 51(11), 1897-1905. [More Information]
Butler, T., Schofield, P., Knight, L., Ton, B., Greenberg, D., Scott, R., Grant, L., Keech, A., Gebski, V., Jones, J., et al (2021). Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): Protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. BMJ Open, 11(9), e044656. [More Information]
Cheng, F., Luk, A., Wu, H., Lim, C., Carroll, L., Tam, C., Fan, B., Yang, A., Lau, E., Ng, A., Keech, A., Joglekar, M., Jenkins, A., Hardikar, A., Ma, R., et al (2021). Shortened relative leukocyte telomere length is associated with all-cause mortality in type 2 diabetes- analysis from the Hong Kong Diabetes Register. Diabetes Research and Clinical Practice, 173, 108649. [More Information]
Woldendorp, K., Doyle, M., Black, D., Ng, M., Keech, A., Grieve, S., Bannon, P. (2021). Subclinical valve thrombosis in transcatheter aortic valve implantation: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 162(5), 1491-1499.e2. [More Information]
Wittert, G., Bracken, K., Robledo, K., Grossmann, M., Yeap, B., Handelsman, D., Stuckey, B., Conway, A., Inder, W., McLachlan, R., Hague, W., Jenkins, A., Gebski, V., Keech, A., et al (2021). Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. The Lancet Diabetes and Endocrinology, 9(1), 32-45. [More Information]
Cao, J., Lee, S., Dunkley, S., Adams, M., Keech, A. (2021). The case for extended thromboprophylaxis in medically hospitalised patients - not yet made. European Journal of Preventive Cardiology, 28(11), 1167-1174. [More Information]
Ong, K., Wu, L., Januszewski, A., O'Connell, R., Xu, A., Scott, R., Sullivan, D., Rye, K., Li, H., Ma, R., Li, L., Gebski, V., Jenkins, A., Keech, A., et al (2021). The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diabetes and Vascular Disease Research, 18(4). [More Information]
Shah, K., Elder, D., Nguyen, M., Turner, L., Doyle, M., Woldendorp, K., Seco, M., Law, C., Wilson, M., Keech, A., Ng, M., Morton, R. (2021). Transcatheter Aortic Valve Implantation (TAVI) Versus Surgical Aortic Valve Replacement for Aortic Stenosis (SAVR): A Cost-Comparison Study. Heart, Lung, and Circulation, 30(12), 1918-1928. [More Information]
Waldman, B., Cartwright, B., Keech, A., Byrom, M., D'Silva, D., Weaver, J. (2021). Transesophageal Echocardiographic Diagnosis of Cardiac Rupture During Extracorporeal Membrane Oxygenation–Assisted Percutaneous Coronary Intervention. Journal of Cardiothoracic and Vascular Anesthesia, 35(3), 910-913. [More Information]

show 27 more

2020

Barraclough, J., Joglekar, M., Januszewski, A., Martínez, G., Celermajer, D., Keech, A., Hardikar, A., Patel, S. (2020). A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. Journal of Cardiovascular Pharmacology and Therapeutics, 25(5), 444-455. [More Information]
Sivashanmugarajah, A., Fulcher, J., Sullivan, D., Elam, M., Jenkins, A., Keech, A. (2020). Author reply. Internal Medicine Journal, 50(4), 507-508. [More Information]
Gencer, B., Mach, F., Guo, J., Im, K., Ruzza, A., Wang, H., Kurtz, C., Pedersen, T., Keech, A., Ott, B., et al (2020). Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 75(18), 2283-2293. [More Information]
Wiviott, S., Giugliano, R., Morrow, D., De Ferrari, G., Lewis, B., Huber, K., Kuder, J., Murphy, S., Forni, D., Kurtz, C., Keech, A., et al (2020). Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. JAMA Cardiology, 5(7), 787-793. [More Information]
Gencer, B., Marston, N., Im, K., Cannon, C., Sever, P., Keech, A., Braunwald, E., Giugliano, R., Sabatine, M. (2020). Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. The Lancet, 396(10263), 1637-1643. [More Information]
Gencer, B., Mach, F., Murphy, S., De Ferrari, G., Huber, K., Lewis, B., Ferreira, J., Kurtz, C., Wang, H., Honarpour, N., Keech, A., et al (2020). Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial Infarction: A Prespecified Secondary Analysis from the FOURIER Trial. JAMA Cardiology, 5(8), 952-957. [More Information]
Januszewski, A., Watson, C., O’Neill, V., McDonald, K., Ledwidge, M., Robson, T., Jenkins, A., Keech, A., McClements, L. (2020). FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Scientific Reports, 10(1), 1-8. [More Information]
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G., Wilcox, I., Keech, A., Rodgers, A., Lal, S. (2020). Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327037 participants. The Lancet Diabetes & Endocrinology, 8(1), 36-49. [More Information]
Scott, E., Januszewski, A., O'Connell, R., Fulcher, G., Scott, R., Kesaniemi, A., Wu, L., Colagiuri, S., Keech, A., Jenkins, A. (2020). Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. Journal of Clinical Endocrinology and Metabolism, 105(10), 1-12. [More Information]
Marston, N., Kamanu, F., Nordio, F., Gurmu, Y., Roselli, C., Sever, P., Pedersen, T., Keech, A., Wang, H., Lira Pineda, A., et al (2020). Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation, 141(8), 616-623. [More Information]
Fulcher, J., Keech, A., Simes, R., Baigent, C., Collins, R. (2020). Questioning statin therapy for older patients – Authors' reply. The Lancet, 395(10240), 1832-1833. [More Information]
Khandkar, C., Vaidya, K., Penglase, R., Cai, K., Shin, J., Hunyor, I., Keech, A., McGill, N. (2020). Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema. Internal Medicine Journal, 50(1), 127-128. [More Information]
Ong, K., Wu, L., Januszewski, A., O'Connell, R., Xu, A., Rye, K., Ma, R., Li, H., Jenkins, A., Jia, W., Keech, A. (2020). Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Research and Clinical Practice, 169, 108450. [More Information]
Cheng, F., Luk, A., Tam, C., Fan, B., Wu, H., Yang, A., Lau, E., Ng, A., Lim, C., Lee, H., Keech, A., Joglekar, M., Jenkins, A., Hardikar, A., Ma, R., et al (2020). Shortened relative leukocyte telomere length is associated with prevalent and incident cardiovascular complications in type 2 diabetes: Analysis from the Hong Kong diabetes register. Diabetes Care, 43(9), 2257-2265. [More Information]
McAuley, S., Lee, M., Paldus, B., Vogrin, S., de Bock, M., Abraham, M., Bach, L., Burt, M., Cohen, N., Colman, P., Holmes-Walker, J., Keech, A., et al (2020). Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: A randomizedcontrolled trial. Diabetes Care, 43(12), 3024-3033. [More Information]
Giugliano, R., Pedersen, T., Saver, J., Sever, P., Keech, A., Bohula, E., Murphy, S., Wasserman, S., Honarpour, N., Wang, H., et al (2020). Stroke Prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients with Stable Atherosclerosis. Stroke, 51(5), 1546-1554. [More Information]
Tarnow-Mordi, W., Abdel-Latif, M., Martin, A., Pammi, M., Robledo, K., Manzoni, P., Osborn, D., Lui, K., Keech, A., Hague, W., Ghadge, A., Brown, R., Isaacs, D., Gordon, A., Askie, L., Deshpande, G., Tracy, M., Sinn, J., Simes, R., et al (2020). The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial. The Lancet Child and Adolescent Health, 4(6), 444-454. [More Information]
Marston, N., Gurmu, Y., Melloni, G., Bonaca, M., Gencer, B., Sever, P., Pedersen, T., Keech, A., Roselli, C., Lubitz, S., et al (2020). The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 141(20), 1600-1607. [More Information]
Cao, J., Waldman, B., O'Connell, R., Sullivan, D., Scott, R., Aryal, N., Gebski, V., Marschner, I., Taskinen, M., Simes, R., McGill, N., Jenkins, A., Keech, A. (2020). Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes, Obesity and Metabolism, 22(8), 1388-1396. [More Information]

show 16 more

2019

Bracken, K., Keech, A., Hague, W., Allan, C., Conway, A., Daniel, M., Gebski, V., Grossmann, M., Handelsman, D., Inder, W., Jenkins, A., Robledo, K., et al (2019). A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial. Clinical Trials, 16(6), 589-598. [More Information]
Mann Zhuang Mills, J., Januszewski, A., Robinson, B., Traill, C., Jenkins, A., Keech, A. (2019). Attractions and barriers to Australian physician-researcher careers. Internal Medicine Journal, 49(2), 171-181. [More Information]
Murphy, S., Pedersen, T., Gaciong, Z., Ceska, R., Ezhov, M., Connolly, D., Jukema, J., Toth, K., Tikkanen, M., Im, K., Keech, A., et al (2019). Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients with Cardiovascular Disease: A Prespecified Analysis from the FOURIER Trial. JAMA Cardiology, 4(7), 613-619. [More Information]
Charytan, D., Sabatine, M., Pedersen, T., Im, K., Park, J., Pineda, A., Wasserman, S., Deedwania, P., Olsson, A., Sever, P., Keech, A., et al (2019). Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. Journal of the American College of Cardiology, 73(23), 2961-2970. [More Information]
Yuan, J., Tan, J., Rajamani, K., Solly, E., King, E., Lecce, L., Simpson, P., Lam, M., Jenkins, A., Bursill, C., Keech, A., Ng, M. (2019). Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARa-Independent Modulation of Thioredoxin Interacting Protein. Diabetes, 68(5), 1040-1053. [More Information]
Xu, D., Jenkins, A., Ryan, C., Keech, A., Brown, A., Bursell, S., O'Dea, K., Brazionis, L. (2019). Health-related behaviours in a remote Indigenous population with Type 2 diabetes: a Central Australian primary care survey in the Telehealth Eye and Associated Medical Services Network [TEAMSnet] project. Diabetic Medicine, 36(12), 1659-1670. [More Information]
Ong, K., Hui, N., Januszewski, A., Kaakoush, N., Xu, A., Fayyad, R., DeMicco, D., Jenkins, A., Keech, A., Waters, D., et al (2019). High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the treating to new targets [TNT] study). Metabolism: Clinical and Experimental, 93, 93-99. [More Information]
Atkinson-Briggs, S., Jenkins, A., Ryan, C., Keech, A., Brazionis, L. (2019). Integrating diabetic retinopathy screening within diabetes education services in Australia's diabetes and indigenous primary care clinics. Internal Medicine Journal, 49(6), 797-800. [More Information]
Qamar, A., Giugliano, R., Keech, A., Kuder, J., Murphy, S., Kurtz, C., Wasserman, S., Sever, P., Pedersen, T., Sabatine, M. (2019). Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA Cardiology, 4(1), 59-63. [More Information]
O'Donoghue, M., Fazio, S., Giugliano, R., Stroes, E., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S., Ceska, R., Keech, A., et al (2019). Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial. Circulation, 139(12), 1483-1492. [More Information]
Scirica, B., Bohula, E., Dwyer, J., Qamar, A., Inzucchi, S., Mcguire, D., Keech, A., Smith, S., Murphy, S., Im, K., et al (2019). Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 139(3), 366-375. [More Information]
Bracken, K., Hague, W., Keech, A., Conway, A., Handelsman, D., Grossmann, M., Jesudason, D., Stuckey, B., Yeap, B., Inder, W., Robledo, K., et al (2019). Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategies. Trials, 20(1), 1-14. [More Information]
Bracken, K., Askie, L., Keech, A., Hague, W., Wittert, G. (2019). Recruitment strategies in randomised controlled trials of men aged 50 years and older: a systematic review. BMJ Open, 9(4), 1-17. [More Information]
Sutanto, S., McLennan, S., Keech, A., Twigg, S. (2019). Shortening of telomere length by metabolic factors in diabetes: protective effects of fenofibrate. Journal of Cell Communication and Signaling, 13(4), 523-530. [More Information]
Sivashanmugarajah, A., Fulcher, J., Sullivan, D., Elam, M., Jenkins, A., Keech, A. (2019). Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects. Internal Medicine Journal, 49(9), 1081-1091. [More Information]
Bracken, K., Keech, A., Hague, W., Kirby, A., Robledo, K., Allan, C., Conway, A., Daniel, M., Gebski, V., Grossmann, M., Handelsman, D., Jenkins, A., et al (2019). Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial. Journal of Clinical Epidemiology, 112, 45-52. [More Information]
Wittert, G., Atlantis, E., Allan, C., Bracken, K., Conway, A., Daniel, M., Gebski, V., Grossmann, M., Hague, W., Handelsman, D., Jenkins, A., Keech, A., Robledo, K., et al (2019). Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomised controlled trial. Diabetes, Obesity and Metabolism, 21(4), 772-780. [More Information]

show 14 more

2018

Bohula, E., Wiviott, S., Mcguire, D., Inzucchi, S., Kuder, J., Im, K., Fanola, C., Qamar, A., Brown, C., Budaj, A., Keech, A., et al (2018). Cardiovascular safety of lorcaserin in overweight or obese patients. New England Journal of Medicine, 379(12), 1107-1117. [More Information]
Sabatine, M., De Ferrari, G., Giugliano, R., Huber, K., Lewis, B., Ferreira, J., Kuder, J., Murphy, S., Wiviott, S., Kurtz, C., Keech, A., et al (2018). Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. Circulation, 38(6), 756-766. [More Information]
Giugliano, R., Keech, A., Sever, P., Pedersen, T., Sabatine, M. (2018). Clinical benefits of evolocumab appear less than hoped – Authors' reply. The Lancet, 391(10124), 934-935. [More Information]
Martin, S., Giugliano, R., Murphy, S., Wasserman, S., Stein, E., Ceska, R., Lopez-Miranda, J., Georgiev, B., Lorenzatti, A., Tikkanen, M., Keech, A., et al (2018). Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, friedewald estimation, and preparative ultracentrifugation insights from the FOURIER trial. JAMA Cardiology, 3(8), 749-753. [More Information]
Simes, R., Robledo, K., White, H., Espinoza, D., Stewart, R., Sullivan, D., Zeller, T., Hague, W., Nestel, P., Glasziou, P., Keech, A., et al (2018). D-dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events and Cancer in Patients with Stable Coronary Heart Disease: LIPID Study. Circulation, 138(7), 712-723. [More Information]
Tarnow-Mordi, W., Morris, J., Kirby, A., Robledo, K., Askie, L., Brown, R., Evans, N., Finlayson, S., Fogarty, M., Gebski, V., Ghadge, A., Hague, W., Isaacs, D., Jeffery, M., Keech, A., Kluckow, M., Popat, H., Sebastian, L., Liley, H., Osborn, D., Simes, R., et al (2018). Delayed Versus Immediate Cord Clamping in Preterm Infants. Obstetrical and Gynecological Survey, 73(5), 265-266. [More Information]
Bohula, E., Scirica, B., Fanola, C., Inzucchi, S., Keech, A., Mcguire, D., Smith, S., Abrahamsen, T., Francis, B., Miao, W., et al (2018). Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American Heart Journal, 202, 39-48. [More Information]
Brazionisb, L., Jenkins, A., Keech, A., Ryan, C., Brown, A., Boffa, J., Bursell, S. (2018). Diabetic retinopathy in a remote Indigenous primary healthcare population: a Central Australian diabetic retinopathy screening study in the Telehealth Eye and Associated Medical Services Network project. Diabetic Medicine, 35(5), 630-639. [More Information]
McAuley, S., De Bock, M., Sundararajan, V., Lee, M., Paldus, B., Ambler, G., Bach, L., Burt, M., Cameron, F., Clarke, P., Holmes-Walker, J., Jenkins, A., Keech, A., et al (2018). Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 8(6), 1-10. [More Information]
Waldman, B., Ansquer, J., Sullivan, D., Jenkins, A., McGill, N., Buizen, L., Davis, T., Best, J., Li, L., Feher, M., Gebski, V., Keech, A., et al (2018). Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. The Lancet Diabetes & Endocrinology, 6(4), 310-318. [More Information]
Bohula, E., Scirica, B., Inzucchi, S., Mcguire, D., Keech, A., Smith, S., Kanevsky, E., Murphy, S., Leiter, L., Dwyer, J., et al (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. The Lancet, 392(10161), 2269-2279. [More Information]
Harmer, J., Keech, A., Veillard, A., Skilton, M., Watts, G., Celermajer, D. (2018). Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: a FIELD substudy. Diabetes Research and Clinical Practice, 141, 156-167. [More Information]
Bohula, E., Giugliano, R., Leiter, L., Verma, S., Park, J., Sever, P., Pineda, A., Honarpour, N., Wang, H., Murphy, S., Keech, A., et al (2018). Inflammatory and cholesterol risk in the FOURIER trial. Circulation, 138(2), 131-140. [More Information]
Bonaca, M., Nault, P., Giugliano, R., Keech, A., Pineda, A., Kanevsky, E., Kuder, J., Murphy, S., Jukema, J., Lewis, B., et al (2018). Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation, 137(4), 338-350. [More Information]
Sullivan, D., Bonnitcha, P., Spinks, C., Keech, A. (2018). PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More. Circulation. Genomic and Precision Medicine, 11(7), 1-3. [More Information]
Koopal, C., Visseren, F., Westerink, J., van der Graaf, Y., Ginsberg, H., Keech, A. (2018). Predicting the effect of fenofibrate on cardiovascular risk for individual patients with type 2 diabetes. Diabetes Care, 41(6), 1244-1250. [More Information]
Larsson, C., Januszewski, A., McGrath, R., Ludvigsson, J., Keech, A., MacIsaac, R., Ward, G., O'Neal, D., Fulcher, G., Jenkins, A. (2018). Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with Type 1 diabetes is common. Internal Medicine Journal, 48(9), 1080-1086. [More Information]

show 14 more

2017

Brazionis, L., Jenkins, A., Keech, A., Ryan, C., Bursell, S. (2017). An evaluation of the telehealth facilitation of diabetes and cardiovascular care in remote Australian Indigenous communities: - Protocol for the telehealth eye and associated medical services network [TEAMSnet] project, a pre-post study design. BMC Health Services Research, 17(1), 1-12. [More Information]
Ong, K., O'Connell, R., Januszewski, A., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Waldman, B., Simes, R., Rye, K., Keech, A., et al (2017). Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study. Clinical Chemistry, 63(7), 1261-1270. [More Information]
Sabatine, M., Leiter, L., Wiviott, S., Giugliano, R., Deedwania, P., De Ferrari, G., Murphy, S., Kuder, J., Gouni-Berthold, I., Keech, A., et al (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The Lancet Diabetes & Endocrinology, 5(12), 941-950. [More Information]
Giugliano, R., Pedersen, T., Park, J., De Ferrari, G., Gaciong, Z., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Keech, A., et al (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. The Lancet, 390(10106), 1962-1971. [More Information]
Giugliano, R., Keech, A., Murphy, S., Huber, K., Tokgozoglu, S., Lewis, B., Ferreira, J., Pineda, A., Somaratne, R., Sever, P., et al (2017). Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiology, 2(12), 1385-1391. [More Information]
Giugliano, R., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T., et al (2017). Cognitive function in a randomized trial of evolocumab. New England Journal of Medicine, 377(7), 633-643. [More Information]
Fonarow, G., Keech, A., Pedersen, T., Giugliano, R., Sever, P., Lindgren, P., van Hout, B., Villa, G., Qian, Y., Somaratne, R., et al (2017). Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiology, 2(10), 1069-1078. [More Information]
Tarnow-Mordi, W., Morris, J., Kirby, A., Robledo, K., Askie, L., Brown, R., Evans, N., Finlayson, S., Fogarty, M., Gebski, V., Ghadge, A., Hague, W., Isaacs, D., Jeffery, M., Keech, A., Kluckow, M., Popat, H., Sebastian, L., Liley, H., Osborn, D., Simes, R., et al (2017). Delayed versus Immediate Cord Clamping in Preterm Infants. New England Journal of Medicine, 377(25), 2445-2455. [More Information]
Giugliano, R., Mach, F., Zavitz, K., Kurtz, C., Schneider, J., Wang, H., Keech, A., Pedersen, T., Sabatine, M., Sever, P., et al (2017). Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clinical Cardiology, 40(2), 59-65. [More Information]
Sabatine, M., Giugliano, R., Keech, A., Honarpour, N., Wiviott, S., Murphy, S., Kuder, J., Wang, H., Liu, T., Wasserman, S., et al (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713-1722. [More Information]
Waldman, B., Jenkins, A., Sullivan, D., Ng, M., Keech, A. (2017). HDL as a Target for Glycemic Control. Current Drug Targets, 18(6), 651-673. [More Information]
Sharman, J., Stanton, T., Reid, C., Keech, A., Roberts-Thomson, P., Stewart, S., Greenough, R., Stowasser, M., Abhayaratna, W. (2017). Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). Contemporary Clinical Trials, 62, 37-42. [More Information]
Keech, A., Jenkins, A. (2017). Triglyceride-lowering trials. Current Opinion in Lipidology, 28(6), 477-487. [More Information]
Gray, B., Kirby, A., Kabunga, P., Freedman, S., Yeates, L., Kanthan, A., Medi, C., Keech, A., Semsarian, C., Sy, R. (2017). Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications. Heart Rhythm, 14(6), 866-874. [More Information]

show 11 more

2016

Chia, N., Fulcher, J., Keech, A. (2016). Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): An evidence-based mnemonic for the treatment of systolic heart failure. Internal Medicine Journal, 46(6), 653-662. [More Information]
Oei, J., Ghadge, A., Coates, E., Wright, I., Saugstad, O., Vento, M., Buonocore, G., Nagashima, T., Suzuki, K., Hosono, S., Askie, L., Keech, A., Tarnow-Mordi, W., et al (2016). Clinicians in 25 countries prefer to use lower levels of oxygen to resuscitate preterm infants at birth. Acta Paediatrica, 105(9), 1061-1066. [More Information]
Bursell, S., Zang, S., Keech, A., Jenkins, A. (2016). Evolving telehealth reimbursement in Australia. Internal Medicine Journal, 46(8), 977-981. [More Information]
Abed, H., Fulcher, J., Kilborn, M., Keech, A. (2016). Inappropriate sinus tachycardia: focus on ivabradine. Internal Medicine Journal, 46(8), 875-883. [More Information]
Hague, W., Simes, R., Kirby, A., Keech, A., White, H., Hunt, D., Nestel, P., Colquhoun, D., Pater, H., Stewart, R., Sullivan, D., et al (2016). Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study. Circulation, 133(19), 1851-1860. [More Information]
Williams, K., Sullivan, D., Veillard, A., O'Brien, R., George, J., Jenkins, A., Young, S., Ehnholm, C., Duffield, A., Twigg, S., Keech, A. (2016). Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine, 33(3), 356-364. [More Information]
Sherrah, A., Andvik, S., van der Linde, D., Davies, L., Bannon, P., Padang, R., Vallely, M., Wilson, M., Keech, A., Jeremy, R. (2016). Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm. Journal of the American College of Cardiology, 67(6), 618-626. [More Information]
Williams, K., Sullivan, D., Nicholson, G., George, J., Jenkins, A., Januszewski, A., Gebski, V., Manning, P., Tan, Y., Donoghoe, M., Buizen, L., Twigg, S., Keech, A., et al (2016). Opposite associations between alanine aminotransferase and Î³-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 65(5), 783-793. [More Information]
Tarnow-Mordi, W., Stenson, B., Kirby, A., Juszczak, E., Donoghoe, M., Deshpande, S., Morley, C., King, A., Doyle, L., Fleck, B., Hague, W., Gebski, V., Ghadge, A., Keech, A., Kluckow, M., Evans, N., Simes, R., et al (2016). Outcomes of two trials of oxygen-saturation targets in preterm infants. New England Journal of Medicine, 374(8), 749-760. [More Information]
Stern, K., Cho, Y., Benitez-Aguirre, P., Jenkins, A., McGill, M., Mitchell, P., Keech, A., Donaghue, K. (2016). QT interval, corrected for heart rate, is associated with HbA1c concentration and autonomic function in diabetes. Diabetic Medicine, 33(10), 1415-1421. [More Information]
Sabatine, M., Giugliano, R., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S., Scott, R., Sever, P., Pedersen, T. (2016). Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal, 173, 94-101. [More Information]
Januszewski, A., Sutanto, S., McLennan, S., O'Neal, D., Keech, A., Twigg, S., Jenkins, A. (2016). Shorter telomeres in adults with Type 1 diabetes correlate with diabetes duration, but only weakly with vascular function and risk factors. Diabetes Research and Clinical Practice, 117, 4-11. [More Information]
Traill, C., Januszewski, A., Larkins, R., Keech, A., Jenkins, A. (2016). Time to research Australian female physician-researchers. Internal Medicine Journal, 46(4), 412-419. [More Information]
Traill, C., Januszewski, A., Larkins, R., Keech, A., Jenkins, A. (2016). Time to research Australian physician-researchers. Internal Medicine Journal, 46(5), 550-558. [More Information]

show 11 more

2015

Jenkins, A., Joglekar, M., Hardikar, A., Keech, A., O'Neal, D., Januszewski, A. (2015). Biomarkers in Diabetic Retinopathy. The Review of Diabetic Studies, 12(1-2), 159-195. [More Information]
Tonkin, A., Blankenberg, S., Kirby, A., Zeller, T., Colquhoun, D., Funke-Kaiser, A., Hague, W., Hunt, D., Keech, A., Nestel, P., Sullivan, D., Simes, R., et al (2015). Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. International Journal of Cardiology, 201, 499-507. [More Information]
Sullivan, D., Watts, G., Nicholls, S., Barter, P., Grenfell, R., Chow, C., Tonkin, A., Keech, A. (2015). Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review. Heart, Lung, and Circulation, 24(5), 495-502. [More Information]
Fulcher, J., O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., Simes, J., Collins, R., Kirby, A., Colhoun, H., Keech, A., et al (2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet, 385(9976), 1397-1405. [More Information]
Harmer, J., Keech, A., Veillard, A., Skilton, M., Marwick, T., Watts, G., Meredith, I., Celermajer, D. (2015). Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. Atherosclerosis, 242(1), 295-302. [More Information]
Swerdlow, D., Preiss, D., Kuchenbaecker, K., Holmes, M., Engmann, J., Shah, T., Sofat, R., Stender, S., Johnson, P., Scott, R., Keech, A., et al (2015). HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet, 385, 351-361. [More Information]
Chin, J., Fulcher, J., Jenkins, A., Keech, A. (2015). Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. Heart, Lung, and Circulation, 24(5), 480-487. [More Information]
Hardikar, A., Satoor, S., Karandikar, M., Joglekar, M., Puranik, A., Wong, W., Kumar, S., Limaye, A., Bhat, D., Januszewski, A., Keech, A., Jenkins, A., et al (2015). Multigenerational Undernutrition Increases Susceptibility to Obesity and Diabetes that Is Not Reversed after Dietary Recuperation. Cell Metabolism, 22(2), 312-319. [More Information]
Ong, K., Januszewski, A., O'Connell, R., Buizen, L., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Rye, K., Keech, A. (2015). Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 59(8), 2035-2044. [More Information]
Herrmann, M., Sullivan, D., Veillard, A., McCorquodale, T., Straub, I., Scott, R., Laakso, M., Topliss, D., Jenkins, A., Blankenberg, S., Keech, A., et al (2015). Serum 25-Hydroxy Vitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes. Diabetes Care, 38(3), 521-528. [More Information]
Ong, K., Januszewski, A., O'Connell, R., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Hung, W., Scott, R., Taskinen, M., Keech, A., Rye, K. (2015). The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 58(3), 464-473. [More Information]

show 8 more

2014

White, H., Tonkin, A., Simes, R., Stewart, R., Robledo, K., Thompson, P., Colquhoun, D., West, M., Nestel, P., Sullivan, D., Keech, A., et al (2014). Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long - Term Coronary Events Following Myocardial Infarction or Unstable Angina. Journal of the American College of Cardiology, 63(4), 345-354. [More Information]
Harmer, J., Keech, A., Veillard, A., Skilton, M., Marwick, T., Watts, G., Meredith, I., Celermajer, D. (2014). Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. Diabetes Research and Clinical Practice, 106(2), 328-336. [More Information]
d'Emden, M., Jenkins, A., Li, L., Zannino, D., Robledo, K., Best, J., Stuckey, B., Park, K., Saltevo, J., Keech, A. (2014). Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia, 57(11), 2296-2303. [More Information]
Waldman, B., Jenkins, A., Davis, T., Taskinen, M., Scott, R., O'Connell, R., Gebski, V., Ng, M., Keech, A. (2014). HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. Diabetes Care, 37(8), 2351-2358. [More Information]
Ding, L., Cheng, R., Hu, Y., Takahashi, Y., Jenkins, A., Keech, A., Humphries, K., Gu, X., Elliott, M., Xia, X., et al (2014). Peroxisome Proliferator-Activated Receptor alpha Protects Capillary Pericytes in the Retina. American Journal of Pathology, 184(10), 2709-2720. [More Information]
Chan, K., Simpson, P., Yong, A., Dunn, L., Chawantanpipat, C., Hsu, C., Yu, Y., Keech, A., Celermajer, D., Ng, M. (2014). The Relationship between Endothelial Progenitor Cell Populations and Epicardial and Microvascular Coronary Disease-A Cellular, Angiographic and Physiologic Study. PloS One, 9(4), 1-12. [More Information]
Boekholdt, S., Hovingh, G., Mora, S., Arsenault, B., Amarenco, P., Pedersen, T., LaRosa, J., Waters, D., DeMicco, D., Simes, R., Keech, A., et al (2014). Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. Journal of the American College of Cardiology, 64(5), 485-494. [More Information]

show 4 more

2013

Sullivan, T., Duque, G., Keech, A., Herrmann, M. (2013). An Old Friend in a New Light: The Role of Osteocalcin in Energy Metabolism. Cardiovascular Therapeutics (Online), 31(2), 65-75. [More Information]
Noonan, J., Jenkins, A., Ma, J., Keech, A., Wang, J., Lamoureux, E. (2013). An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes. Diabetes, 62(12), 3968-3975. [More Information]
Ghosh, J., Martin, A., Keech, A., Chan, K., Gomes, S., Singarayar, S., McGuire, M. (2013). Balloon Warming Time Is the Strongest Predictor Of Late Pulmonary Vein Electrical Reconnection Following Balloon Cryoablation for Atrial Fibrillation. Heart Rhythm, 10(9), 1311-1317. [More Information]
White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, I., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
Ting, R., Keech, A. (2013). Fenofibrate and renal disease: Clinical effects in diabetes. Clinical Lipidology, 8(6), 669-680. [More Information]
Simo, R., Roy, S., Behar-Cohen, F., Keech, A., Mitchell, P., Wong, T. (2013). Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Current Medicinal Chemistry, 20(26), 3258-3266. [More Information]
Olver, I., Keech, A. (2013). Forming networks for research: proposal for an Australian clinical trials alliance. Medical Journal of Australia, 198(5), 254-255. [More Information]
Dignan, R., Keech, A., Gebski, V., Robledo, K., Hughes, C. (2013). Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. International Journal of Cardiology, 168(6), 5378-5384. [More Information]
Chan, K., O'Connell, R., Sullivan, D., Hoffmann, L., Rajamani, K., Whiting, M., Donoghoe, M., Vanhala, M., Hamer, A., Yu, B., Stocker, R., Ng, M., Keech, A. (2013). Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (field) study. Diabetologia, 56(4), 724-736. [More Information]
Hankey, G., Anderson, N., Ting, R., Veillard, A., Romo, M., Wosik, M., Sullivan, D., O'Connell, R., Hunt, D., Keech, A. (2013). Rates and predictors of risk of stroke and its subtypes in diabetes: A prospective observational study. Journal of Neurology, Neurosurgery and Psychiatry, 84(3), 281-287. [More Information]
Chen, Y., Hu, Y., Lin, M., Jenkins, A., Keech, A., Mott, R., Lyons, T., Ma, J. (2013). Therapeutic Effects of PPARÎ± Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. Diabetes, 62(1), 261-272. [More Information]

show 8 more

2012

Donaghue, K., Keech, A., Craig, M., O'Connell, P. (2012). A 'cure' for diabetes and its complications. In Louise A. Baur, Stephen M. Twigg, Roger S.Magnusson (Eds.), A Modern Epidemic: Expert Perspectives on Obesity and Diabetes, (pp. 401-420). Sydney, Australia: Sydney University Press.
Ting, R., Keech, A., Drury, P., Donoghoe, M., Hedley, J., Jenkins, A., Davis, T., Lehto, S., Celermajer, D., Simes, R., Rajamani, K., et al (2012). Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment - The FIELD Study. Diabetes Care, 35(2), 218-225. [More Information]
Tonkin, A., Hunt, D., Voysey, M., Kesaniemi, Y., Hamer, A., Waites, J., Mahar, L., Mann, S., Glasziou, P., Forder, P., Simes, R., Keech, A. (2012). Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. American Heart Journal, 163(3), 508-514. [More Information]
Jun, M., Zhu, B., Tonelli, M., Jardine, M., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., Perkovic, V. (2012). Effects of Fibrates in Kidney Disease: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 60(20), 2061-2071. [More Information]
Best, J., Drury, P., Davis, T., Taskinen, M., Kesaniemi, Y., Scott, R., Pardy, C., Voysey, M., Keech, A. (2012). Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort. Diabetes Care, 35(5), 1165-1170. [More Information]
Emberson, J., Kearney, P., Blackwell, L., Newman, C., Reith, C., Bhala, N., Holland, L., Peto, R., Keech, A., Collins, R., Simes, R., et al (2012). Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175 000 people in 27 randomised trials of statin therapy. PloS One, 7(1), 1-10. [More Information]
Preiss, D., Tikkanen, M., Welsh, P., Ford, I., Lovato, L., Elam, M., laRosa, J., DeMicco, D., Colhoun, H., Goldenberg, I., Keech, A., et al (2012). Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis. JAMA, 308(8), 804-811. [More Information]
Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
Herrmann, M., Whiting, M., Veillard, A., Ehnholm, C., Sullivan, D., Keech, A. (2012). Plasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD study. Clinical Chemistry and Laboratory Medicine, 50(12), 2213-2219. [More Information]
Mihaylova, B., Emberson, J., Keech, A., Collins, R., Baigent, C. (2012). Statins for people at low risk of cardiovascular disease - Authors' reply. The Lancet, 380(9856), 1817-1818. [More Information]
Fulcher, J., Keech, A. (2012). The case for more intensive use of statins. Therapeutic Advances in Chronic Diseases, 3(5), 201-210. [More Information]
Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, R., Barnes, E., Voysey, M., Gray, A., Collins, R., Baigent, C., et al (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590. [More Information]
Ng, M., Yong, A., Ho, M., Shah, M., Chawantanpipat, C., O'Connell, R., Keech, A., Kritharides, L., Fearon, W. (2012). The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 5(4), 515-522. [More Information]
Keech, A., Simes, R., Fulcher, J. (2012). The role of statin therapy in patients with lower vascular risk. Medical Journal of Australia, 197(3), 130-131. [More Information]

show 11 more

2011

Sullivan, D., Forder, P., Simes, R., Whiting, M., Kritharides, L., Merrifield, A., Donoghoe, M., Colman, P., Neil, G., Haapamaki, H., Keech, A. (2011). Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice, 94(2), 284-290. [More Information]
Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
Drury, P., Ting, R., Zannino, D., Ehnholm, C., Flack, J., Whiting, M., Fassett, R., Ansquer, J., Dixon, P., Davis, T., Pardy, C., Keech, A., et al (2011). Estimated Glomerular Filtration Rate and Albuminuria are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(1), 32-43. [More Information]
Scott, R., Donoghoe, M., Watts, G., O'Brien, R., Pardy, C., Taskinen, M., Davis, T., Colman, P., Manning, P., Fulcher, G., Keech, A. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10(1), 102-1-102-8. [More Information]
Hayes, A., Clarke, P., Voysey, M., Keech, A. (2011). Simulation of Quality-Adjusted Survival in Chronic Diseases: An Application in Type 2 Diabetes. Medical Decision Making, 31(4), 559-570. [More Information]

show 2 more

2010

Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PloS One, 5(1), e8580-1-e8580-10. [More Information]
Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Robledo, K., Simes, R., Best, J., Hamwood, S., Keech, A. (2010). Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 53(9), 1846-1855. [More Information]
Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., Keech, A., Simes, R., et al (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. [More Information]
Burgess, D., Hunt, D., Li, L., Zannino, D., Williamson, E., Davis, T., Laakso, M., Kesaniemi, Y., Zhang, J., Sy, R., Keech, A., et al (2010). Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. European Heart Journal, 31(1), 92-99. [More Information]
Chan, K., Chawantanpipat, C., Gattorna, T., Chantadansuwan, T., Kirby, A., Madden, A., Keech, A., Ng, M. (2010). The relationship between coronary stenosis severity and compression type coronary artery movement in acute myocardial infarction. American Heart Journal, 159(4), 584-592. [More Information]

show 3 more

2009

Keech, A., Horowitz, J. (2009). Cost-effectiveness Considerations of Cardiovascular Therapeutics. Heart, Lung, and Circulation, 18(2), 118-122. [More Information]
Rajamani, K., Coleman, P., Li, L., Best, J., Voysey, M., D'Emden, M., Laakso, M., Baker, J., Keech, A., FIELD study investigators, F. (2009). Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. The Lancet, 373(9677), 1780-1788. [More Information]
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Boey (Tse), D., Taskinen, M., Ehnholm, C., Keech, A., FIELD study investigators, F. (2009). Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 32(3), 493-498. [More Information]
Soderberg, S., Colquhoun, D., Keech, A., Yallop, J., Barnes, E., Pollicino, C., Simes, R., Tonkin, A., Nestel, P. (2009). Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity, 33(1), 123-130. [More Information]
Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009). Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 950-955. [More Information]
Clarke, P., Hayes, A., Glasziou, P., Scott, R., Simes, R., Keech, A. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61-68. [More Information]

show 3 more

2008

Cook, D., Keech, A., Gebski, V., Pike, R., Wonders, S. (2008). Balancing the outcomes: reporting harms (adverse events). In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 132-142). Sydney: AMPCo.
Hayes, A., Clarke, P., Glasziou, P., Simes, R., Drury, P., Keech, A. (2008). Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care, 31(4), 795-797. [More Information]
Kearney, P., Blackwell, L., Collins, R., Keech, A., Simes, R., Peto, R., Armitage, J., Baigent, C. (2008). Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet, 371, 117-125. [More Information]
Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - author's reply. The Lancet, 371, 722.
Keech, A., Mitchell, P., Summanen, P., Davis, T., Simes, R. (2008). Fenofibrate and diabetic retinopathy - Authors' reply. The Lancet, 371(9614), 722-722. [More Information]
Keech, A., Mitchell, P. (2008). FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy. Review of Endocrinology.
Hiukka, A., Westerbacka, J., Leinonen, E., Watanabe, H., Wiklund, O., Hulten, L., Salonen, J., Tuomainen, T., Yki-Jarvinen, H., Keech, A., et al (2008). Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. Journal of the American College of Cardiology, 52(25), 2190-2197. [More Information]
Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008). Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry, 54(6), 1038-1045. [More Information]
Kearney, P., Keech, A., Simes, R., Collins, R. (2008). Statins and diabetes: authors' reply. The Lancet, 371(9626), 1752-1752.

show 6 more

2007

Scott, R., D'Emden, M., Best, J., Drury, P., Ehnholm, C., Kesaniemi, Y., Pardy, C., Tse, D., Barter, P., Taskinen, M., Copt, S., Keech, A., et al (2007). Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate. Circulation, 116, II_838.
Keech, A., Gebski, V., Forder, P. (2007). Allocation concealment and blinding: when ignorance is bliss. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 54-64). Sydney: AMPCo.
Gebski, V., Keech, A., Simes, R. (2007). Applying subgroup analysis to individual patient decisions. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 114-122). Sydney: AMPCo.
Marschner, I., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
Davis, W., Davis, T., Keech, A. (2007). Calculating cardiovascular risk in people with diabetes. Diabetes Management Journal, 18(March), 32-32.
Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
Keech, A., Gebski, V., Vachan, B. (2007). Flow of participants in randomised studies. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 347-349). Sydney: AMPCo.
Keech, A., Gebski, V., Heritier, S. (2007). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 92-98). Sydney: AMPCo.
Keech, A., Gebski, V., Pike, R. (2007). Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials. Sydney: AMPCo.
Keech, A., Pike, R., Granger, R., Gebski, V. (2007). Interpreting the results of a clinical trial. Medical Journal of Australia, 186(9), 318-319. [More Information]
Keech, A., Ghersi, D., Gebski, V., Pike, R. (2007). Introducing the report of a randomised controlled trial: the title, abstract, scientific background and rationale. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 8-10). Sydney: AMPCo.
Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A., Taskinen, M. (2007). Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia, 50(10), 2067-2075. [More Information]
O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.
Keech, A., Gebski, V. (2007). Managing the resource demand of a large sample in clinical trials: can you succeed with fewer subjects? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 39-45). Sydney: AMPCo.
Keech, A., Gebski, V., Lord, S. (2007). Multiple analyses in clinical trials: sound science or data dredging? In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 123-131). Sydney: AMPCo.
Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. Medical Journal of Australia, 186(7), 368-370. [More Information]
Gebski, V., Beller, E., Keech, A., Van Der Weyden, M. (2007). Randomised Controlled Trials: Elements of a Good Study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 7-22). Sydney: AMPCo.
Keech, A., Gebski, V., Beller, E., Van Der Weyden, M. (2007). Randomised controlled trials: elements of a good study. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 1-7). Sydney: AMPCo.
Brighton, J., Gebski, V., Keech, A. (2007). Specifying intervention in a clinical trial. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 16-20). Sydney: AMPCo.
Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.

show 17 more

2006

Keech, A. (2006). Challenges in undertaking primary prevention trials. 54th Annual Scientific Meeting of the Cardiac Society of Australian and New Zealand.
Keech, A., Simes, R. (2006). Clinical trial design & management: The role of PPAR-ALPHA agonists in prevention of CVD. Atherosclerosis Supplements, 7(3), 174-174.
Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). Correction to the FIELD study report. The Lancet, 368(9545), 1415. [More Information]
Keech, A. (2006). Effects of long-term fenofibrate therapy in the FIELD study. Meeting of the Taiwan Endocrine Society.
Keech, A. (2006). Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The FIELD study, a randomised controlled trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment - Reply. The Lancet, 367(9509), 470-471.
Baigent, C., Keech, A., Kearney, P., Collins, R., Simes, R. (2006). Efficacy and safety of cholesterol-lowering treatment-authors' reply [letter]. The Lancet, 367(9509), 470-471. [More Information]
Keech, A., Best, J. (2006). Highlights from the FIELD trial: a landmark trial. Annual Scientific Sessions of the American Diabetes Association.
Sullivan, D., Forder, P., Simes, R., Whiting, M., Keech, A. (2006). Individual and combined effects of fenofibrate and sulphonylureas on HDL cholesterol and outcomes. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Alexander, K., Newby, L., Bhapkar, M., White, H., Hochman, J., Pfisterer, M., Moliterno, D., Peterson, E., Van de Werf, F., Simes, R., Keech, A., et al (2006). International variation in invasive care of the elderly with acute coronary syndromes. European Heart Journal, 27(13), 1558-1564. [More Information]
Burgess, D., Kilborn, M., Keech, A. (2006). Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. European Heart Journal, 27(23), 2846-2857. [More Information]
Keech, A. (2006). Issues in clinical trial design and management: example of the role of PPAR-alpha agonists in prevention of CVD, satellite symposium. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Keech, A. (2006). Metabolic syndrome and diabetes. NHLBI National Cholesterol Education Program (USA).
Grieve, S., Ansquer, J., Keech, A. (2006). Micronized fenofibrate: A useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology, 2(6), 635-646. [More Information]
Colquhoun, D., Soderberg, S., Kirby, A., Keech, A., Simes, R., Hague, W., Hamilton-Craig, I., Tonkin, A. (2006). Obesity and adipokines as risk factors for major coronary heart disease events in patients with CHD: Results from the lipid trial. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Hiukka, A., Leinonen, E., Hilden, H., Perttunen-Nio, H., Keech, A., Taskinen, M. (2006). Reduction of large VLDL particles by fenofibrate is associated with reduction of small dense LDL in type 2 diabetes: Field Helsinki substudy. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Keech, A. (2006). Role of PPAR-alpha agonists in diabetic disease. Metabolic Syndrome Institute Meeting.
Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective - [Response]. Journal of the National Cancer Institute, 98(17), 1021-1022. [More Information]
Gebski, V., Lagleva, M., Keech, A., Simes, R., Langlands, A. (2006). Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. Journal of the National Cancer Institute, 98(1), 26-38. [More Information]
Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). The FIELD study - Reply. The Lancet, 367(9517), 1142-1143. [More Information]
Keech, A. (2006). To manage diabetes: management in the early stages. Solvay Scientific Meeting.

show 18 more

2005

Gebski, V., Lagleva, M., Simes, R., Keech, A., Langlands, A. (2005). Adjuvant Radiotherapy in Early Breast Cancer: The Clinical Utility of Published Meta-Analysis. RANZCR, 55th Annual Scientific Meeting.
Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding [reply]. Medical Journal of Australia, 183(3), 165-166.
Forder, P., Gebski, V., Keech, A. (2005). Allocation concealment and blinding: when ignorance is bliss. Medical Journal of Australia, 182(2), 87-89. [More Information]
McAvoy, B., Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., Neale, M., Pollock, C., et al (2005). An evidence based clinical aid for cardiovascular disease--what do GPs think? Australian Family Physician, 34(4), 297-298. [More Information]
Gebski, V., Heritier, S., Pillai, A., Luke, V., Simes, R., Keech, A. (2005). Computer modelling of adaptive randomisation schemes in large scale randomised controlled trials. 20th International Workshop on Statistical Modelling, Sydney, Australia: University of Western Sydney.
Briffa, T., Eckermann, S., Griffiths, A., Harris, P., Heath, M., Freedman, B., Donaldson, L., Briffa, N., Keech, A. (2005). Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Medical Journal of Australia, 183(9), 450-455. [More Information]
Keech, A. (2005). Developing evidence-based practice in Diabetes care: FIELD, a Landmark Trial. American Diabetes Association 2005.
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with chronic kidney disease and diabetes mellitus. Hypertension, 46(4), 900-901.
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, R., Isles, C., Furberg, C., et al (2005). Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology, 16(12), 3748-3754. [More Information]
Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M., Forder, P., Pillai, A., Davis, T., Glasziou, P., Sullivan, D., MacMahon, S., et al (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849-1861. [More Information]
Baigent, C., Keech, A., Kearney, P., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267-1278. [More Information]
Scott, R., Best, J., Forder, P., Taskinen, M., Simes, R., Barter, P., Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovascular Diabetology, 4(13), 1-9. [More Information]
Keech, A. (2005). FIELD study: a large scale trial of fibrate therapy in diabetes. ASEAN Federation of Endocrine Societies.
Lundman, P., Keech, A., Griffiths, K., Pillai, A., Celermajer, D. (2005). New carotid plaque formation is very common in adult patients with Type 2 diabetes mellitus. Diabetic Medicine, 22(3), 355-356. [More Information]
Keech, A. (2005). The long-term efficacy and safety of Fenofibrate therapy to prevent cardiovascular events in 9795 people with type 2 diabetes mellitus: the main results of the FIELD study. American Heart Association Annual Scientific Sessions.
Keech, A., Grieve, S., Patel, A., Griffiths, K., Skilton, M., Watts, G., Marwick, T., Groshens, M., Celermajer, D. (2005). Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. Diabetic Medicine, 22(11), 1558-1565. [More Information]

show 13 more

2004

Keech, A., Wonders, S., Cook, D., Gebski, V. (2004). Balancing the outcomes: reporting adverse events. Medical Journal of Australia, 181(4), 215-218.
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. The Lancet, 363(9411), 757-767. [More Information]
Keech, A. (2004). Effects of fenofibrate on lipid parameters in Type 2 Diabetes: a large-scale trial to prevent cardiovascular disease. 40th Annual Meeting of the EASD.
Colquhoun, D., Keech, A., Hunt, D., Marschner, I., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
Seale, J., Gebski, V., Keech, A. (2004). Generalising the results of trials to clinical practice. Medical Journal of Australia, 181(10), 558-560. [More Information]
O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.
Lord, S., Gebski, V., Keech, A. (2004). Multiple Analyses In Clinical Trials: Sound Science Or Data Dredging? Medical Journal of Australia, 181(8), 452-454.
Keech, A. (2004). PBAC review of eligibility criteria for lipid lowering drugs.
Keech, A. (2004). Rationale for a large-scale trial of fenofibrate to prevent cardiovascular disease in Type 2 Diabetes. Fournier Symposium; Taiwan Endocrinology & Diabetes Association Meeting.
Keech, A., Best, J., Scott, R., Barter, P., Simes, R., Forder, P., Taskinen, M., FIELD study investigators, F. (2004). Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes. Journal of the American College of Cardiology, 43(5), A462-A462.
Keech, A. (2004). Significant lipid changes with fenofibrate in Type 2 Diabetes in a large-scale trial to prevent cardiovascular disease. APSAVD Meeting.
Cook, D., Gebski, V., Keech, A. (2004). Subgroup analysis in clinical trials. Medical Journal of Australia, 180(6), 289-291.
Simes, R., Gebski, V., Keech, A. (2004). Subgroup analysis: application to individual patient decisions. Medical Journal of Australia, 180(9), 467-469. [More Information]
Barter, P., Best, J., Coleman, P., D'Emden, M., Davis, T., Drury, P., Ehnholm, C., Keech, A., Simes, R., et al (2004). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology, 3(December), 9 - 1-9 - 11. [More Information]

show 11 more

2003

Sniderman, A., Furberg, C., Keech, A., Roeters van Lennep, J., Frohlich, J., Jungner, I., Walldius, G. (2003). Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. The Lancet, 361(9359), 777-780. [More Information]
Burgess, D., Gebski, V., Keech, A. (2003). Baseline data in clinical trials. Medical Journal of Australia, 11, 105-107.
Pike, R., Keech, A., Simes, R. (2003). Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002. Medical Journal of Australia, 178(7), 316-317.
Kirby, A., Gebski, V., Keech, A. (2003). Determining the sample size in a clinical trial [in reply]. Medical Journal of Australia, 178(7), 358-358. [More Information]
Vachan, B., Gebski, V., Keech, A. (2003). Flow of participants in randomised studies. Medical Journal of Australia, 178, 347-349.
Heritier, S., Gebski, V., Keech, A. (2003). Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Medical Journal of Australia, 11, 438-440.
Keech, A. (2003). Logistics of large scale studies in diabetes and vascular studies â€“ FIELD & HPS. Australian Nurses Cardiovascular & Hypertension Association.
Keech, A., Gebski, V. (2003). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects. Medical Journal of Australia, 178(7), 356-357.
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., et al (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet, 361(9374), 2005-2016. [More Information]
Fulcher, G., Amerena, J., Conner, G., Beltrame, J., Hankey, G., Keech, A., Lloyd, B., McAvoy, B., Neale, M., Pollock, C., et al (2003). Prevention of cardiovascular disease: an evidence-based clinical aid. MJA Focus, (21 July 2003), 1-14.
Hague, W., Gebski, V., Keech, A. (2003). Recruitment to randomised studies. Medical Journal of Australia, 178(11), 579-581.
Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al (2003). Secondary prevention of cardio vascular events with long-term Pravastatin in patients with diabetes or impared fasting glucose: results from the LIPID trial. Diabetes Care, 26(10), 2713-2721. [More Information]
Gebski, V., Keech, A. (2003). Statistical methods in clinical trials. Medical Journal of Australia, 11, 182-184.
Keech, A. (2003). The Heart Protection Study: Results and clinical implications for treatment of patients in the Asia-Pacific and international lipid guidelines. International Atherosclerosis Society.
Keech, A. (2003). The link between Chronic Inflammation, Obesity and Endothelial Dysfunction. Cardiac Society of Australia & New Zealand.

show 12 more

2002

Keech, A. (2002). An update on clinical trials in diabetes. Australian Diabetes Society.
Keech, A. (2002). Approaches to the patient with metabolic syndrome. ASEANZ 2002.
Keech, A. (2002). Challenges in the prevention of atherosclerosis in the Asia-Pacific region. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
Keech, A. (2002). Clinical Trials: drug or class effects? 14th ASEAN Congress of Cardiology.
Kilian, J., Keech, A., Adams, M., Celermajer, D. (2002). Coronary collateralization: determinants of adequate distal vessel filling after arterial occlusion. Coronary Artery Disease, 13(3), 155-159. [More Information]
Sacks, F., Tonkin, A., Craven, T., Pfeffer, M., Shepherd, J., Keech, A., Furberg, C., Braunwald, E. (2002). Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105(12), 1424-1428.
Kirby, A., Gebski, V., Keech, A. (2002). Determining the sample size in a clinical trial. Medical Journal of Australia, 177(5), 256-257.
Neal, B., MacMahon, S., Ohkubo, T., Tonkin, A., Wilcken, D., Keech, A. (2002). Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. European Heart Journal, 23(19), 1509-1515. [More Information]
Simes, R., Furberg, C., Braunwald, E., Davis, B., Ford, I., Tonkin, A., Shepherd, J., Keech, A. (2002). Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. European Heart Journal, 23(3), 207-215. [More Information]
Keech, A., Neal, B., MacMahon, S., Ohkubo, T., Brnabic, A., Tonkin, A. (2002). Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. Journal Of The Renin-Angiotensin-Aldosterone System, 3(4), 270-276. [More Information]
Keech, A. (2002). Evidence-based clinical practice in diabetes. European Association of Diabetes Societies.
Keech, A. (2002). HDL cholesterol: a new therapeutic target for CHD prevention. 3rd World Congress of the Asia-Pacific Society of Atherosclerosis and Vascular Diseases.
Simes, R., Kirby, A., Keech, A., Hague, W., MacMahon, S., Hunt, D., Tonkin, A., Alyward, P., Colquhoun, D., Glasziou, P., et al (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow up. The Lancet, 359, 1379-1387. [More Information]
Keech, A., Gebski, V. (2002). Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? Medical Journal of Australia, 177(8), 437-439.
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360, 23-33. [More Information]
Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R., Meade, T., Youngman, L., Buxton, M., de Bono, D., George, C., Keech, A., Lindley, R., et al (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360(9326, 6 July 2002), 7-22. [More Information]
Keech, A. (2002). New insights from the Heart Protection Study. Asian Congress of Cardiology. Asian Congress of Cardiology.
Keech, A. (2002). Principles of prospective meta-analysis. Clinical Trials Symposium.
Beller, E., Gebski, V., Keech, A. (2002). Randomisation in clinical trials. Medical Journal of Australia, 177(10), 565-567. [More Information]
Simes, R., Keech, A., et al (2002). Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 105(3), 316-321.
Keech, A. (2002). Rationale, results and implications of the Heart Protection Study. Malaysian Medical Society Meeting.
Keech, A. (2002). Recent advances in clinical trials for treatment of atherosclerosis in diabetes. Australian Health & Medical Research Congress 2002.
Simes, R., Marschner, I., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169. [More Information]
Richie, G., Keech, A., Yamamoto,, A., Nakamura, H., Hosoda,, S., Nobuyoshi,, M., Matsuzaki, M., Tan, C., Mabuchi, H., Horibe, H., et al (2002). Risk factors for coronary heart disease in the Japanese - Comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Journal of Atherosclerosis and Thrombosis, 9(4), 191-199.
Pfeffer, M., Keech, A., Sacks, F., Cobbe, S., Tonkin, A., Byington, R., Davis, B., Friedman, C., Braunwald, E. (2002). Safety and tolerability of pravastatin in long-term clinical trials. Circulation, 105(20), 2341-2346. [More Information]
Brighton, J., Gebski, V., Keech, A. (2002). Specifying interventions in a clinical trial. Medical Journal of Australia, 176(6), 281-282. [More Information]
Gebski, V., Marschner, I., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492. [More Information]

show 24 more

2001

Ritchie, G., Keech, A. (2001). Asia-Pacific collaboration on coronary heart disease risk factor intervention: study desing and methods. Heart, Lung, and Circulation, 10, 24-29. [More Information]
Hughes, C., Keech, A., Cox,, N. (2001). Myocardial infarction due to saphenous vein graft compression by an extracardiac mass. Heart, Lung, and Circulation, 10, 35-37.
Gebski, V., Beller, E., Keech, A. (2001). Randomized controlled trails: elements of a good study. Medical Journal of Australia, 175, 272-274.
Ghersi, D., Gebski, V., Keech, A. (2001). Scientific background and rationale for a randomised controlled trial. Medical Journal of Australia, 175(7), 386-386. [More Information]
Keech, A., Gebski, V. (2001). Selecting participants for clinical trials. Medical Journal of Australia, 175(9), 490-491. [More Information]

show 2 more

2000

Miller, O., Tang, S., Keech, A., Pigott, N., Beller, E., Celermajer, D. (2000). Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. The Lancet, 356(9240), 1464-1469. [More Information]

Selected Grants

2022

A randomised clinical trial of a digital self management program for people with Interstitial Lung Disease (REBUILD-SM trial), Corte T, Holland A, Chambers D, Palmer A, Glaspole I, Moodley Y, Keech A, Laranjo L, Knibbs L, Troy L, Cox N, Cox I, Goh N, Troy L, Department of Health and Aged Care (Federal - administered by NHMRC)/MRFF 2021 Chronic Respiratory Conditions
COLCARDIO-ACS cognitive substudy (COG), Keech A, Brain and Mind Centre/National Heart Foundation Vanguard Grant

2021

New Frontiers in Personalised Prevention of Coronary Artery Disease, Figtree G, Celemajer D, Chow C, Fazekas de St Groth B, Drummond G, Ellinor P, Grieve S, Jenkins A, Kassiou M, Keech A, Kovacic J, Larance M, Marwick T, McGuire H, Meikle P, Nicholls S, O'Sullivan J, Peter K, Ritchie R, Shaw J, Simes R, Walley T, Wilson A, Department of Health and Aged Care (Federal)/MRFF - Frontier Health and Medical Research Program, Stage One
Digital solutions for heart failure best practice care, Keech A, Lal S, Macdonald P, Ferguson C, Ryan C, Jenkins A, Dempsey K, O'Connell R, Kilov G, Department of Health and Aged Care (Federal)/MRFF - Cardiovascular Health Mission
SAFER (AUS) Trial: Screening for Atrial Fibrillation with ECG to Reduce stroke - a randomised controlled trial, Freedman B, Nelson M, Keech A, Lowres N, Hespe C, Cadilhac D, Mant J, Thijs V, Simes R, Department of Health and Aged Care (Federal - administered by NHMRC)/MRFF International Clinical Trial Collaborations
Efficacy and Value In ExpeDited out of hospital arrEst care ANd ECMO CPR (ECPR) The EVIDENCE Study, Dennis M, Burns B, Keech A, Moylan E, NSW Health/Translational Research Grants Scheme

2019

COLchicine CARDIovascular Outcomes in Acute Coronary Syndrome COLCARDIO-ACS Study, Keech A, Patel S, Hillis G, Nicholls S, Thompson P, Newby D, Simes R, Morton R, Gebski V, Psaltis P, National Health and Medical Research Council (NHMRC)/Clinical Trials and Cohort Studies

2018

Better Outcomes through Innovations in Clinical Trials: from Personalised Medicine to Population Health, Simes R, Keech A, Gebski V, Stockler M, Jenkins A, National Health and Medical Research Council (NHMRC)/Program Grants
Long term Study of LDL-c Lowering with Evolocumab: Observational Follow-up after the FOURIER Outcomes Study FOURIER LEGACY Study, Keech A, Amgen Foundation/Research Support
Economic Evaluation of Transcatheter Aortic Valve Implantation TAVI versus Surgical Aortic Valve Replacement SAVR in adults of all risk categories - Part 1, Morton R, Ng M, Keech A, Edwards Lifesciences/Research Grant

2017

Restoring Microcirculatory Perfusion in ST-elevation Myocardial Infarction: The RESTORE MI study, Ng M, Fearon W, Yong A, Keech A, White H, Layland J, National Health and Medical Research Council (NHMRC)/Project Grants
Innovations in prevention and treatment of vascular disease, Keech A, National Health and Medical Research Council (NHMRC)/Research Fellowships
FIELD NOvel Molecular markers in Diabetes NOMAD, Jenkins A, Sullivan D, Hardikar A, Molloy M, Sullivan D, Galande S, Ma R, Keech A, National Health and Medical Research Council (NHMRC)/Project Grants

2016

Evaluation of the efficacy and cost-effectiveness of long-term hybrid closed loop insulin delivery in improving glycaemia, psychosocial wellbeing, sleep quality, cognition, and biochemical markers of vascular risk in adults with type 1 diabetes compared wi, O'Neal D, Speight J, Keech A, Juvenile Diabetes Research Foundation - JDRF (Australia)/Australian Type 1 Diabetes Clinical Research Network: Centres and Concept Proposals
CONCEPT A - The Fenofibrate and Microvascular Events FAME 1 Eye Study - Preventing Vision Loss in T1 Diabetes, Jenkins A, Hardikar A, Keech A, Juvenile Diabetes Research Foundation - JDRF (Australia)/Australian Type 1 Diabetes Clinical Research Network: Centres and Concept Proposals

2015

Biomarkers for Risk and Outcomes of Type 2 Diabetes: A Discovery and Validation Approach in Australian and Chinese subjects, Keech A, Jenkins A, Sullivan D, Hardikar A, Ma R, Jia W, Wang Y, Li H, National Health and Medical Research Council (NHMRC)/National Natural Science Foundation of China (NSFC)
Diabetic Retinopathy - Closing the Loop for Diabetic Eye Care and Complication Risk Mitigation, Keech A, Jenkins A, Henderson T, Brown A, Bursell S, Brazionis L, Craig J, Maple-Brown L, O'Dea K, Gebski V, National Health and Medical Research Council (NHMRC)/Centres of Research Excellence

2014

A well characterised biobank of individuals with type 2 diabetes, Keech A, Gebski V, Davies L, Rebecca L Cooper Medical Research Foundation/Research Support

2013

Purchase of the Retina Tomograph Platform with Corneal Confocal Microscope module, Jenkins A, Keech A, National Health and Medical Research Council (NHMRC)/Equipment Grant

2012

FIELD LIFE Study: Unlocking gene - environment interactions in Type 2 diabetes and its complications, Keech A, Hardikar A, Jenkins A, Blankenberg S, Best J, National Health and Medical Research Council (NHMRC)/Project Grants
FIELD LIFE: Epigenetics of Type 2 diabetes complications, Jenkins A, Keech A, National Health and Medical Research Council (NHMRC)/Project Grants
Advancing the evidence base for care and policy in priority health areas, Simes R, Keech A, Gebski V, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner I, National Health and Medical Research Council (NHMRC)/Program Grants

2011

Senior Principal Research Fellowship, Keech A, National Health and Medical Research Council (NHMRC)/Career Awards: Research Fellowships
Cobas Integra 400+ Biochemical Analyzer, Keech A, National Health and Medical Research Council (NHMRC)/Equipment Grant
A calculator for personalised HbA1c targets for individuals with type 2 diabetes, Colagiuri S, Keech A, Australian Diabetes Society/ADS-Servier National Action Plan Grants in Memory of Barry Young
Peripheral vascular disease in type 2 diabetes, Keech A, Royal Australasian College of Physicians/Scholarship

2010

Reducing Impulsive Behaviour in Repeat Violent Offenders Using a Selective Serotonin Reuptake Inhibitor (Zoloft), Gebski V, Keech A, Chappell D, National Health and Medical Research Council (NHMRC)/Partnership Projects
China-Australia Collaborations in Diabetes and Obesity Research, Keech A, Office of Global Engagement/IPDF Grant

2009

Unlocking genetic factors predicting type 2 diabetes complications for clinical practice: The Field Study, Keech A, Best J, Jenkins A, Sullivan D, Twigg S, National Health and Medical Research Council (NHMRC)/Project Grants

2008

Evaluating whether eye blood vessel changes predict heart disease in people with deabetes., Keech A, Mitchell P, National Heart Foundation of Australia/Grants-in-Aid

2007

Clinical trials advances for better health outcomes, Simes R, Keech A, Gebski V, Stockler M, National Health and Medical Research Council (NHMRC)/Project Grants

2006

FIELD Biomarker studies, Keech A, Laboratories Fournier (France)/Research Support
NHMRC - Research Fellowship, Keech A, National Health and Medical Research Council (NHMRC)/Established Career Fellowships
Biomarkers and genetic determinants of cardiovascular risk in diabetes: the FIELD study, Keech A, National Health and Medical Research Council (NHMRC)/Project Grants

2005

Nhmrc Clinical Trials Centre Clinical Trials Methodology And Practice Consultancy, Incorporating Utilisation And Enhancement Of A Web-Based Electronic Clinical Trials Data Management System And Repository, Keech A, Simes R, Gebski V, Hague W, Stockler M, National Health and Medical Research Council (NHMRC)/Enabling Grants
TBA: Roche Diagnostics, Gebski V, Hughes C, Keech A, Dignan R, Roche Products Pty Ltd/Research Grant
FIELD substudies, research and analysis., Keech A, Simes R, Laboratoires Fournier/Research grant

2004

Assessment and research related services on medical technologies and procedures to MSAC., Keech A, Commonwealth Department of Health and Ageing/Research and Development
LIPID and LIPID Cohort Studies (BMS), Hague W, Keech A, Simes R, Bristol Myers Squibb/Research Grant

2002

Advances in clinical trials research and evidence-based decision making, Gebski V, Keech A, Marschner I, Simes R, Stockler M, National Health and Medical Research Council (NHMRC)/Program Grants
4 x Ultra-low temperature freezers with racks and auto dial alarm system, Keech A, National Health and Medical Research Council (NHMRC)/Equipment Grant

2001

NHMRC Clinical Trials Centre, Keech A, Simes R, National Health and Medical Research Council (NHMRC)/Centres of Clinical Research Excellence
Clinical medical and science research, Keech A, National Health and Medical Research Council (NHMRC)/Established Career Fellowships
Research Fellowship, Keech A, University of Sydney/Research & Development

1999

Heart Protection Study UK Med Research Council, Collins R, Keech A, Peto R P, Sleight P, UK Medical Research Council (MRC UK)/Research Grant
TBA: Merck Asia, Keech A, Ritchie G, Merck Asia/Project Grant
Vascular reactivity substudy, Celermajer D, Keech A, FIELD/Not Known
The HERO-2 study., Keech A, Simes R, The Medicines Company (USA)/Project Grant
Provision of assessment and research related services on medical technologies and procedures for the Medical Services Advisory Committee (MSAC), Eckermann S, Eckermann S, Gebski V, Ghersi D, Howard K, Irwig L, Keech A, Lord S, Salkeld G, Simes R, Stockler M, Department of Health and Aged Care (Federal)/Research Support
Asian audit study, Keech A, Merck Sharpe and Dohme Australia Pty Ltd/MSD Research Foundation
Field study: Clinical trial of drugs, Keech A, Laboratories Fournier (France)/Research Support
Symphony, Keech A, Simes R, The Cleveland Clinic Foundation/Contract Research

Faculty of Medicine and Health

Page not found

Professor Anthony Keech

Selected publications

Publications

Selected Grants

2022

2021

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2002

2001

1999

Related research articles

Sydney researchers receive 31 Investigator grants

Heart disease stroke research receives 12 4 million federal funding boost

Statin therapy found safe and effective for people over 75 years

Universities convene for the Sino-Australian Research Symposium

20 years of statins: how they changed heart health forever